netmhciipan_version	peptide_length	brackets	score_total	hotspot_max	prediction_type	biotherapeutic_category	compound_groups	total_protein_length	pref_name	usan_stem_definition	biotherapeutic_description	IMGT_mAb_DB_species	macromolecule_size_category
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	765	41	ba	Mouse antibodies	Phase III & approved biologics	657	ABAGOVOMAB	monoclonal antibodies	Abagovomab (mouse mab)	Mus musculus	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	113	48	ba	NA	Phase III & approved biologics	383	ABATACEPT	receptor molecules or membrane ligands, natural, modified or modified: T-cell receptors	1-25-oncostatin M (human precursor) fusion protein with CTLA-4 (antigen) (human) fusion protein with immunoglobulin G1 (human heavy chain fragment), bimolecular (146-146')-disulfide	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	472	43	ba	Chimeric antibodies	Phase III & approved biologics	664	ABCIXIMAB	monoclonal antibodies	Abciximab (chimeric Fab)	Chimeric	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	253	84	ba	Human antibodies	Phase III & approved biologics	667	ADUCANUMAB	monoclonal antibodies	Aducanumab (human mab)	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	5	2	ba	NA	Phase III & approved biologics	431	AFLIBERCEPT	receptor molecules or membrane ligands, natural, modified or modified: vascular endothelial growth factor (VEGF) receptors	Aflibercept (immunoadhesin)	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Uncategorized enzymes	Phase III & approved biologics	398	AGALSIDASE ALFA	enzymes	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Uncategorized enzymes	Phase III & approved biologics	398	AGALSIDASE BETA	enzymes	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Other uncategorized biologics	Phase III & approved biologics	585	ALBUMIN, CHROMATED CR 51 SERUM	NA	Serum albumin precursor	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Other uncategorized biologics	Phase III & approved biologics	585	ALBUMIN, IODINATED I 125 SERUM	iodine-containing contrast media	Serum albumin precursor	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Other uncategorized biologics	Phase III & approved biologics	585	ALBUMIN, IODINATED I 131 SERUM	iodine-containing contrast media	Serum albumin precursor	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	49	32	ba	Non-human, non-murine biologics	Phase III & approved biologics	132	ALDESLEUKIN	interleukins: interleukin-2 analogues and derivatives	Interleukin-2 precursor (IL-2) (T-cell growth factor)	Homo sapiens	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	35	14	ba	NA	Phase III & approved biologics	457	ALEFACEPT	receptor molecules or membrane ligands, natural, modified or modified: lymphocyte function-associated antigen 3 (LFA) receptors	Lymphocyte function-associated antigen 3 precursor (Ag3) (Antigen CD58)	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	429	84	ba	Humanized antibodies	Phase III & approved biologics	662	ALEMTUZUMAB	monoclonal antibodies	Immunoglobulin G 1 (human-rat monodonal CAMPATH-1H 71-chain anti-human antigen CD52), disulfide with human-rat monoclonal CAMPATH-1H light chain, dimer	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	323	24	ba	Uncategorized enzymes	Phase III & approved biologics	201	ALFIMEPRASE	enzymes	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Uncategorized enzymes	Phase III & approved biologics	497	ALGLUCERASE	enzymes	Glucosylceramidase precursor (Beta-glucocerebrosidase) (Acid beta-glucosidase)	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	59	17	ba	Uncategorized enzymes	Phase III & approved biologics	896	ALGLUCOSIDASE ALFA	enzymes	Human lysosomal prepro-alpha-glucosidase-(57-952)-peptide 199-arginine-223-histidine variant	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	218	86	ba	Human antibodies	Phase III & approved biologics	667	ALIROCUMAB	monoclonal antibodies	Alirocumab (human mab)	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	552	86	ba	Human antibodies	Phase III & approved biologics	1332	AMIVANTAMAB	monoclonal antibodies	NA	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	209	86	ba	Human antibodies	Phase III & approved biologics	661	AMUBARVIMAB	monoclonal antibodies	NA	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Non-human, non-murine biologics	Phase III & approved biologics	153	ANAKINRA	interleukin receptor antagonists: interleukin-1 (IL-1) receptor antagonists	Interleukin-1 receptor antagonist protein precursor (IL-1ra) (IRAP)	Homo sapiens	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	189	84	ba	Chimeric antibodies	Phase III & approved biologics	214	ANDECALIXIMAB	monoclonal antibodies	NA	Chimeric	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Other uncategorized biologics	Phase III & approved biologics	359	ANDEXANET ALFA	NA	Andexanet alfa	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	283	86	ba	Human antibodies	Phase III & approved biologics	662	ANIFROLUMAB	monoclonal antibodies	Anifrolumab (human mab)	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	498	95	ba	Humanized antibodies	Phase III & approved biologics	663	ANSUVIMAB	monoclonal antibodies	NA	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Other uncategorized biologics	Phase III & approved biologics	432	ANTITHROMBIN ALFA	NA	Antithrombin-III precursor (ATIII) (PRO0309)	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Uncategorized enzymes	Phase III & approved biologics	1353	APADAMTASE ALFA	enzymes	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	82	24	ba	Human antibodies	Phase III & approved biologics	667	APITEGROMAB	monoclonal antibodies	NA	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	142	73	ba	Other uncategorized biologics	Phase III & approved biologics	58	APROTININ	NA	Pancreatic trypsin inhibitor precursor (Basic protease inhibitor) (BPI)	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	1	1	ba	Non-human, non-murine biologics	Phase III & approved biologics	726	ASFOTASE ALFA	enzymes	Asfotase alfa	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	1043	57	ba	Uncategorized enzymes	Phase III & approved biologics	327	ASPARAGINASE ERWINIA CHRYSANTHEMI	enzymes	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	148	84	ba	Human antibodies	Phase III & approved biologics	661	ASTEGOLIMAB	monoclonal antibodies	NA	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	2	2	ba	NA	Phase III & approved biologics	313	ATACICEPT	receptor molecules or membrane ligands, natural, modified or modified	Atacicept (immunoadhesin)	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	307	84	ba	Humanized antibodies	Phase III & approved biologics	662	ATEZOLIZUMAB	monoclonal antibodies	NA	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	179	86	ba	Human antibodies	Phase III & approved biologics	661	ATOLTIVIMAB	monoclonal antibodies	NA	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	59	17	ba	Uncategorized enzymes	Phase III & approved biologics	896	AVALGLUCOSIDASE ALFA	enzymes	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	197	52	ba	Human antibodies	Phase III & approved biologics	666	AVELUMAB	monoclonal antibodies	NA	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Other uncategorized biologics	Phase III & approved biologics	28	AVIPTADIL	vasodilators (undefined group)	NA	NA	<50 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Other uncategorized biologics	Phase III & approved biologics	112	AVOTERMIN	growth factors: bone morphogenetic proteins; growth factors: transforming growth factors	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	123	84	ba	Human antibodies	Phase III & approved biologics	653	BALSTILIMAB	monoclonal antibodies	NA	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	352	84	ba	Human antibodies	Phase III & approved biologics	669	BAMLANIVIMAB	monoclonal antibodies	NA	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	434	86	ba	Chimeric antibodies	Phase III & approved biologics	656	BASILIXIMAB	monoclonal antibodies	Basiliximab (chimeric mab)	Chimeric	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	74	21	ba	NA	Phase III & approved biologics	426	BATIRAXCEPT	receptor molecules or membrane ligands, natural, modified or modified	NA	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	192	31	ba	Human antibodies	Phase III & approved biologics	664	BATOCLIMAB	monoclonal antibodies	NA	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	352	42	ba	Chimeric antibodies	Phase III & approved biologics	664	BAVITUXIMAB	monoclonal antibodies	Bavituximab (chimeric mab)	Chimeric	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Other uncategorized biologics	Phase III & approved biologics	109	BECAPLERMIN	growth factors: platelet derived growth factors	Platelet-derived growth factor, B chain precursor (PDGF B-chain) (Platelet-derived growth factor beta polypeptide)	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	256	86	ba	Humanized antibodies	Phase III & approved biologics	665	BELANTAMAB MAFODOTIN	synthetic analogs of the dolastatin series; monoclonal antibodies	NA	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	13	6	ba	NA	Phase III & approved biologics	357	BELATACEPT	receptor molecules or membrane ligands, natural, modified or modified: T-cell receptors	Belatacept (immunoadhesin)	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	49	32	ba	Non-human, non-murine biologics	Phase III & approved biologics	132	BEMPEGALDESLEUKIN	interleukins: interleukin-2 analogues and derivatives; PEGylated compounds, covalent attachment of macrogol (polyethylene glycol) polymer	NA	Homo sapiens	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	447	86	ba	Humanized antibodies	Phase III & approved biologics	660	BENMELSTOBART	NA	NA	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	319	84	ba	Humanized antibodies	Phase III & approved biologics	665	BENRALIZUMAB	monoclonal antibodies	Benralizumab (humanized mab)	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	227	23	ba	Human antibodies	Phase III & approved biologics	450	BENTRACIMAB	monoclonal antibodies	NA	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	370	59	ba	Humanized antibodies	Phase III & approved biologics	666	BERMEKIMAB	monoclonal antibodies	RA-18C3 (mab)	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	318	84	ba	Humanized antibodies	Phase III & approved biologics	445	BEVACIZUMAB	monoclonal antibodies	Immunoglobulin G 1 (human-mouse monoclonal rhuMAb-VEGF 7-chain anti-human vascular endothelial growth factor), disulfide with human-mouse monoclonal rhuMAb-VEGF light chain, dimer	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	167	84	ba	Human antibodies	Phase III & approved biologics	664	BEZLOTOXUMAB	monoclonal antibodies	Bezlotoxumab (human mab)	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	173	43	ba	Human antibodies	Phase III & approved biologics	661	BIMAGRUMAB	monoclonal antibodies	Bimagrumab (human mab)	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	329	84	ba	Humanized antibodies	Phase III & approved biologics	669	BIMEKIZUMAB	monoclonal antibodies	NA	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	197	52	ba	Non-human, non-murine biologics	Phase III & approved biologics	823	BINTRAFUSP ALFA	fusion proteins	NA	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	324	84	ba	Chimeric antibodies	Phase III & approved biologics	668	BIRTAMIMAB	monoclonal antibodies	NA	Chimeric	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	6	6	ba	Other uncategorized biologics	Phase III & approved biologics	20	BIVALIRUDIN	anticoagulants (hirudin type)	NA	NA	<50 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	518	33	ba	Mouse antibodies	Phase III & approved biologics	504	BLINATUMOMAB	monoclonal antibodies	Blinatumumab (human BiTE)	Mus musculus	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	22	5	ba	Non-human, non-murine biologics	Phase III & approved biologics	290	BLISIBIMOD	immunomodulators	Blisibimod (mab)	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	315	86	ba	Humanized antibodies	Phase III & approved biologics	658	BOCOCIZUMAB	monoclonal antibodies	Bococizumab (humanized mab)	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	78	12	ba	Human antibodies	Phase III & approved biologics	667	BRAZIKUMAB	monoclonal antibodies	NA	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	421	86	ba	Chimeric antibodies	Phase III & approved biologics	664	BRENTUXIMAB VEDOTIN	synthetic analogs of the dolastatin series; monoclonal antibodies	Brentuximab Vedotin (chimeric mab)	Chimeric	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	120	35	ba	Human antibodies	Phase III & approved biologics	662	BRIAKINUMAB	monoclonal antibodies	Briakinumab (human mab)	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	215	84	ba	Human antibodies	Phase III & approved biologics	656	BRODALUMAB	monoclonal antibodies	Brodalumab (human mab)	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	355	46	ba	Humanized antibodies	Phase III & approved biologics	252	BROLUCIZUMAB	monoclonal antibodies	NA	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	194	75	ba	Human antibodies	Phase III & approved biologics	660	BUROSUMAB	monoclonal antibodies	NA	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	535	68	ba	Chimeric antibodies	Phase III & approved biologics	927	CADONILIMAB	monoclonal antibodies	NA	Chimeric	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	4	4	ba	Other uncategorized biologics	Phase III & approved biologics	32	CALCITONIN SALMON	vitamin D analogs; anti-inflammatory agents (salicylic acid derivatives)	NA	NA	<50 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	375	75	ba	Human antibodies	Phase III & approved biologics	842	CANAKINUMAB	monoclonal antibodies	Immunoglobulin G1, anti-[Homo sapiens interleukin 1, beta (IL1B)] human monoclonal ACZ885; gamma1 heavy chain (Homo sapiens VH-IGHG1*03) (221-214’)-disulfide with kappa light chain (Homo sapiens V-KAPPA-IGKC*01); (227-227’’:230-230’’)-bisdisulfide dimer	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	324	41	ba	Humanized antibodies	Phase III & approved biologics	259	CAPLACIZUMAB	monoclonal antibodies	Caplacizumab (humanized mab)	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	438	68	ba	Chimeric antibodies	Phase III & approved biologics	661	CAROTUXIMAB	monoclonal antibodies	TRC-105 (chimeric mab)	Chimeric	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Therapeutic peptides	Phase III & approved biologics	28	CARPERITIDE	peptides: atrial natriuretic type substances	CARPERITIDE	NA	<50 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	305	84	ba	Human antibodies	Phase III & approved biologics	664	CASIRIVIMAB	monoclonal antibodies	NA	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Other uncategorized biologics	Phase III & approved biologics	731	CATRIDECACOG	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	338	78	ba	Human antibodies	Phase III & approved biologics	658	CEMIPLIMAB	monoclonal antibodies	NA	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	389	84	ba	Humanized antibodies	Phase III & approved biologics	667	CENDAKIMAB	monoclonal antibodies	NA	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Non-human, non-murine biologics	Phase III & approved biologics	165	CEPEGINTERFERON ALFA-2B	PEGylated compounds, covalent attachment of macrogol (polyethylene glycol) polymer	NA	Homo sapiens	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Uncategorized enzymes	Phase III & approved biologics	544	CERLIPONASE ALFA	enzymes	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	212	84	ba	Human antibodies	Phase III & approved biologics	664	CETRELIMAB	monoclonal antibodies	NA	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	498	68	ba	Chimeric antibodies	Phase III & approved biologics	665	CETUXIMAB	monoclonal antibodies	Immunoglobulin G 1 (human-mouse monoclonal C225 yt-chain anti-human epidermal growth factor receptor), disulfide with human-mouse monoclonal C225 x-chain, dimer	Chimeric	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Uncategorized atropines	Phase III & approved biologics	237	CHORIOGONADOTROPIN ALFA	tricyclic compounds; atropine derivatives	Choriogonadotropin beta chain [Precursor]; Glycoprotein hormones alpha chain [Precursor];	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	233	84	ba	Human antibodies	Phase III & approved biologics	680	CILGAVIMAB	monoclonal antibodies	NA	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	931	65	ba	Other uncategorized biologics	Phase III & approved biologics	468	CINTREDEKIN BESUDOTOX	interleukins	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Uncategorized enzymes	Phase III & approved biologics	896	CIPAGLUCOSIDASE ALFA	enzymes	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	427	84	ba	Humanized antibodies	Phase III & approved biologics	667	CLAZAKIZUMAB	monoclonal antibodies	Clazakizumab (humanized mab)	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	398	86	ba	Human antibodies	Phase III & approved biologics	671	CLESROVIMAB	monoclonal antibodies	NA	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	1872	63	ba	Uncategorized enzymes	Phase III & approved biologics	1021	COLLAGENASE CLOSTRIDIUM HISTOLYTICUM	enzymes; quaternary ammonium derivatives	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	6	2	ba	NA	Phase III & approved biologics	526	CONBERCEPT	receptor molecules or membrane ligands, natural, modified or modified: vascular endothelial growth factor (VEGF) receptors	Conbercept (mab)	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	265	84	ba	Humanized antibodies	Phase III & approved biologics	667	CONCIZUMAB	monoclonal antibodies	NA	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Other uncategorized biologics	Phase III & approved biologics	478	CONESTAT ALFA	enzyme inhibitors	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Non-human, non-murine biologics	Phase III & approved biologics	231	CORIFOLLITROPIN ALFA	tricyclic compounds; atropine derivatives	NA	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	81	23	ba	Other uncategorized biologics	Phase III & approved biologics	41	CORTICORELIN	prehormones or hormone-release stimulating peptides	NA	NA	<50 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	13	7	ba	Other uncategorized biologics	Phase III & approved biologics	41	CORTICORELIN OVINE TRIFLUTATE	prehormones or hormone-release stimulating peptides; vinca alkaloids	Corticoliberin precursor (Corticotropin-releasing factor) (CRF)	NA	<50 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	18	9	ba	Uncategorized atropines	Phase III & approved biologics	39	CORTICOTROPIN	tricyclic compounds; atropine derivatives	Corticotropin-lipotropin precursor (Pro-opiomelanocortin) (POMC)	NA	<50 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	18	9	ba	Uncategorized atropines	Phase III & approved biologics	39	CORTICOTROPIN ZINC HYDROXIDE	tricyclic compounds; atropine derivatives	Corticotropin-lipotropin precursor (Pro-opiomelanocortin) (POMC)	NA	<50 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	152	27	ba	Human antibodies	Phase III & approved biologics	668	COSIBELIMAB	monoclonal antibodies	NA	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	173	84	ba	Humanized antibodies	Phase III & approved biologics	657	CRENEZUMAB	monoclonal antibodies	Crenezumab (humanized mab)	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	260	84	ba	Humanized antibodies	Phase III & approved biologics	666	CRIZANLIZUMAB	monoclonal antibodies	NA	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	256	84	ba	Chimeric antibodies	Phase III & approved biologics	668	CROVALIMAB	monoclonal antibodies	NA	Chimeric	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	336	52	ba	Humanized antibodies	Phase III & approved biologics	652	DACLIZUMAB	monoclonal antibodies	Daclizumab (humanized mab)	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	19	11	ba	NA	Phase III & approved biologics	328	DALANTERCEPT	receptor molecules or membrane ligands, natural, modified or modified: transforming growth factor receptors	Delantercept (mab)	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	331	84	ba	Human antibodies	Phase III & approved biologics	666	DARATUMUMAB	monoclonal antibodies	Daratumumab (human mab)	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	16	10	ba	Non-human, non-murine biologics	Phase III & approved biologics	165	DARBEPOETIN ALFA	erythropoietins	Erythropoietin precursor (Epoetin)	Homo sapiens	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	406	86	ba	Humanized antibodies	Phase III & approved biologics	665	DATOPOTAMAB DERUXTECAN	monoclonal antibodies; antineoplastics (camptothecin derivatives)	NA	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	4330	78	ba	Other uncategorized biologics	Phase III & approved biologics	1285	DAXIBOTULINUMTOXINA	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	346	84	ba	Humanized antibodies	Phase III & approved biologics	662	DAZUKIBART	NA	NA	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	878	56	ba	Non-human, non-murine biologics	Phase III & approved biologics	521	DENILEUKIN DIFTITOX	interleukins: interleukin-2 analogues and derivatives	Diphtheria toxin precursor (DT) (NAD(+)--diphthamide ADP-ribosyltransferase)	Corynebacterium diphtheriae	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	378	86	ba	Chimeric antibodies	Phase III & approved biologics	660	DEPATUXIZUMAB MAFODOTIN	synthetic analogs of the dolastatin series; monoclonal antibodies	NA	Chimeric	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	305	86	ba	Humanized antibodies	Phase III & approved biologics	669	DEPEMOKIMAB	monoclonal antibodies	NA	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Other uncategorized biologics	Phase III & approved biologics	114	DIBOTERMIN ALFA	growth factors: bone morphogenetic proteins; growth factors: transforming growth factors	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	365	68	ba	Chimeric antibodies	Phase III & approved biologics	663	DINUTUXIMAB	monoclonal antibodies	Dinutuximab (chimeric human-mouse mab	Chimeric	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	454	84	ba	Humanized antibodies	Phase III & approved biologics	662	DOMVANALIMAB	monoclonal antibodies; narcotic agonists/antagonists (normorphine type)	NA	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	328	86	ba	Humanized antibodies	Phase III & approved biologics	663	DONANEMAB	monoclonal antibodies	NA	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Uncategorized enzymes	Phase III & approved biologics	260	DORNASE ALFA	enzymes	Deoxyribonuclease I precursor (DNase I) (Dornase alfa)	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	312	86	ba	Humanized antibodies	Phase III & approved biologics	657	DOSTARLIMAB	monoclonal antibodies	NA	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Other uncategorized biologics	Phase III & approved biologics	262	DROTRECOGIN ALFA (ACTIVATED)	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	32	9	ba	Non-human, non-murine biologics	Phase III & approved biologics	275	DULAGLUTIDE	peptides: glucagon-like peptide (GLP) analogs	NA	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	173	84	ba	Human antibodies	Phase III & approved biologics	666	DURVALUMAB	monoclonal antibodies	Durvalumab (human mab)	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	14	7	ba	Therapeutic peptides	Phase III & approved biologics	60	ECALLANTIDE	peptides	[Glu20,Ala21,Arg36,Ala38,His39,Pro40,Trp42]tissue factor pathway inhibitor (human)-(20-79)-peptide (modified on reactive bond region Kunitz inhibitor 1 domain containing fragment)	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	63	36	ba	Non-human, non-murine biologics	Phase III & approved biologics	227	EFGARTIGIMOD ALFA	Fc fusion protein; immunomodulators	NA	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	23	6	ba	Non-human, non-murine biologics	Phase III & approved biologics	260	EFPEGLENATIDE	Fc fusion protein; PEGylated compounds, covalent attachment of macrogol (polyethylene glycol) polymer; peptides: exendin-4-derivatives	NA	Heloderma suspectum	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	269	54	ba	Human antibodies	Phase III & approved biologics	256	EFUNGUMAB	Fc fusion protein; monoclonal antibodies	Efungumab (human scFv)	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	285	84	ba	Humanized antibodies	Phase III & approved biologics	663	ELOTUZUMAB	monoclonal antibodies	Elotuzumab (humanized mab)	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	688	86	ba	Human antibodies	Phase III & approved biologics	1322	ELRANATAMAB	monoclonal antibodies	NA	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	340	86	ba	Humanized antibodies	Phase III & approved biologics	659	EMACTUZUMAB	monoclonal antibodies	NA	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	17	4	ba	Human antibodies	Phase III & approved biologics	670	EMAPALUMAB	monoclonal antibodies	NA	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	251	84	ba	Humanized antibodies	Phase III & approved biologics	1106	EMICIZUMAB	monoclonal antibodies	NA	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	340	84	ba	Human antibodies	Phase III & approved biologics	660	ENFORTUMAB VEDOTIN	synthetic analogs of the dolastatin series; monoclonal antibodies	Enfortumab vedotin (human mab)	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	23	15	ba	Other uncategorized biologics	Phase III & approved biologics	36	ENFUVIRTIDE	peptides: antiviral peptides; antivirals	Acetyl-L-tyrosyl-L-threonyl-L-seryl-L-leucyl-L-isoleucyl-L-histidyl-L-seryl­L-leucyl-L-isoleucyl-L-alpha-glutamyl-L-alpha-giutamyl-L-seryl-L-glutaminyl­L-asparaginyl-L-glutaminyl-L-glutaminyI-L-alpha-glutamyl-L-Iysyl-L-asparaginyl­L-alpha-glutamyl-L-glutaminyl-L-alpha-glutamyl-L-leucyl-L-leucyl-L-alpha-glutamyl-L-leucyl­L-alpha-aspartyl-L-Iysyl-L-tryptophyl-L-alanyl-L-seryl-L-leucyl-L-tryptophyl­L-asparaginyl-L-tryptophyl-L-phenylalaninamide	NA	<50 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Uncategorized enzymes	Phase III & approved biologics	395	EPAFIPASE	enzymes	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	474	86	ba	Human antibodies	Phase III & approved biologics	1334	EPCORITAMAB	monoclonal antibodies	NA	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Other uncategorized biologics	Phase III & approved biologics	165	EPOETIN DELTA	erythropoietins	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	317	84	ba	Humanized antibodies	Phase III & approved biologics	660	EPTINEZUMAB	monoclonal antibodies	NA	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Other uncategorized biologics	Phase III & approved biologics	139	EPTOTERMIN ALFA	growth factors: bone morphogenetic proteins; growth factors: transforming growth factors	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	199	64	ba	Human antibodies	Phase III & approved biologics	672	ERENUMAB	monoclonal antibodies	NA	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	35	14	ba	NA	Phase III & approved biologics	467	ETANERCEPT	receptor molecules or membrane ligands, natural, modified or modified: tumor necrosis factor receptors	Tumor necrosis factor receptor superfamily member 1B precursor (Tumor necrosis factor receptor 2) (p80)	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	363	86	ba	Human antibodies	Phase III & approved biologics	665	ETESEVIMAB	monoclonal antibodies	NA	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	224	84	ba	Humanized antibodies	Phase III & approved biologics	660	ETROLIZUMAB	monoclonal antibodies	Etrolizumab (humanized mab)	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	299	86	ba	Human antibodies	Phase III & approved biologics	667	EVINACUMAB	monoclonal antibodies; vinca alkaloids	NA	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	62	12	ba	Human antibodies	Phase III & approved biologics	656	EVOLOCUMAB	monoclonal antibodies	Evolocumab (human mab)	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	301	43	ba	Uncategorized enzymes	Phase III & approved biologics	244	EXEBACASE	enzymes	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	47	15	ba	Therapeutic peptides	Phase III & approved biologics	39	EXENATIDE	peptides: exendin-4-derivatives	EXENATIDE	NA	<50 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	601	84	ba	Human antibodies	Phase III & approved biologics	1343	FARICIMAB	monoclonal antibodies	NA	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	333	84	ba	Humanized antibodies	Phase III & approved biologics	666	FARLETUZUMAB	monoclonal antibodies	Farletuzumab (humanized mab)	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	366	84	ba	Human antibodies	Phase III & approved biologics	660	FASINUMAB	monoclonal antibodies	Fasinumab (human mab)	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	217	84	ba	Humanized antibodies	Phase III & approved biologics	664	FAVEZELIMAB	monoclonal antibodies	NA	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	290	86	ba	Humanized antibodies	Phase III & approved biologics	661	FELADILIMAB	vasodilators (undefined group); monoclonal antibodies	NA	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	252	84	ba	Human antibodies	Phase III & approved biologics	663	FIANLIMAB	monoclonal antibodies	NA	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Other uncategorized biologics	Phase III & approved biologics	1705	FIBRINOGEN I 125	NA	Fibrinogen alpha/alpha-E chain precursor	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	334	86	ba	Human antibodies	Phase III & approved biologics	534	FIGITUMUMAB	monoclonal antibodies	Figitumumab (human mab)	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Non-human, non-murine biologics	Phase III & approved biologics	175	FILGRASTIM	colony-stimulating factors: granulocyte colony-stimulating factors (G-CSF)	Granulocyte colony-stimulating factor precursor (G-CSF) (Pluripoietin)	Homo sapiens	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Uncategorized atropines	Phase III & approved biologics	203	FOLLITROPIN	tricyclic compounds; atropine derivatives	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Uncategorized atropines	Phase III & approved biologics	203	FOLLITROPIN ALFA	tricyclic compounds; atropine derivatives	Follitropin beta chain precursor (Follicle-stimulating hormone beta subunit) (FSH-beta)	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Uncategorized atropines	Phase III & approved biologics	203	FOLLITROPIN BETA	tricyclic compounds; atropine derivatives	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Uncategorized atropines	Phase III & approved biologics	203	FOLLITROPIN DELTA	tricyclic compounds; atropine derivatives	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Other uncategorized biologics	Phase III & approved biologics	21	FORIGERIMOD ACETATE	immunomodulators	NA	NA	<50 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	417	86	ba	Humanized antibodies	Phase III & approved biologics	662	FREMANEZUMAB	monoclonal antibodies	NA	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	351	84	ba	Human antibodies	Phase III & approved biologics	663	FULRANUMAB	monoclonal antibodies	Fulranumab (human mab)	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	393	86	ba	Chimeric antibodies	Phase III & approved biologics	666	FUTUXIMAB	monoclonal antibodies	Futuximab (chimeric mab)	Chimeric	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	227	84	ba	Humanized antibodies	Phase III & approved biologics	659	GALCANEZUMAB	monoclonal antibodies	NA	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Other uncategorized biologics	Phase III & approved biologics	60	GALINPEPIMUT-S	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Uncategorized enzymes	Phase III & approved biologics	495	GALSULFASE	enzymes	N-acetylgalactosamine 4-sulfatase (human CSL4S-342 cell)	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	155	84	ba	Human antibodies	Phase III & approved biologics	663	GANITUMAB	monoclonal antibodies	Ganitumab (human mab)	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	258	84	ba	Human antibodies	Phase III & approved biologics	671	GANTENERUMAB	monoclonal antibodies	Gantenerumab (human mab)	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	279	84	ba	Humanized antibodies	Phase III & approved biologics	668	GARETOSMAB	monoclonal antibodies	NA	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	301	35	ba	Chimeric antibodies	Phase III & approved biologics	264	GEFURULIMAB	monoclonal antibodies	NA	Chimeric	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	406	86	ba	Humanized antibodies	Phase III & approved biologics	659	GEVOKIZUMAB	monoclonal antibodies	Gevokizumab (humanized mab)	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	603	86	ba	Chimeric antibodies	Phase III & approved biologics	663	GIRENTUXIMAB	monoclonal antibodies	Girentuximab (chimeric mab)	Chimeric	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	965	84	ba	Humanized antibodies	Phase III & approved biologics	1574	GLOFITAMAB	monoclonal antibodies	NA	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Other uncategorized biologics	Phase III & approved biologics	29	GLUCAGON HYDROCHLORIDE	NA	NA	NA	<50 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	1283	51	ba	Uncategorized enzymes	Phase III & approved biologics	415	GLUCARPIDASE	enzymes	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Other uncategorized biologics	Phase III & approved biologics	237	GONADOTROPIN, CHORIONIC	atropine derivatives	Choriogonadotropin beta chain [Precursor]; Glycoprotein hormones alpha chain [Precursor];	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	274	86	ba	Humanized antibodies	Phase III & approved biologics	668	GOTISTOBART	NA	NA	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	61	10	ba	Human antibodies	Phase III & approved biologics	663	GUSELKUMAB	monoclonal antibodies	Guselkumab (human mab)	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	376	84	ba	Human antibodies	Phase III & approved biologics	669	IANALUMAB	monoclonal antibodies; narcotic agonists/antagonists (normorphine type)	NA	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	340	86	ba	Humanized antibodies	Phase III & approved biologics	668	IBALIZUMAB	monoclonal antibodies	Ibalizumab (humanized mab)	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	1039	85	ba	Mouse antibodies	Phase III & approved biologics	652	IBRITUMOMAB TIUXETAN	monoclonal antibodies; chelating agents	Immunoglobulin G1, anti-(human CD20 (antigen)) (mouse monoclonal IDEC­Y2B8 71-chain), disulfide with mouse monoclonal IDEC-Y2B8 x-chain, dimer, iV-[2-[bis(carboxymethyl)amino]-3-(4-isothiocyanatophenyl) propyl]­iV-[2-[bis(carboxymethyl) amino]propyl]glycine conjugate	Mus musculus	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	460	84	ba	Humanized antibodies	Phase III & approved biologics	444	IDARUCIZUMAB	monoclonal antibodies	NA	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	109	23	ba	Human antibodies	Phase III & approved biologics	666	IMDEVIMAB	monoclonal antibodies	NA	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Uncategorized enzymes	Phase III & approved biologics	497	IMIGLUCERASE	enzymes	Glucosylceramidase precursor (Beta-glucocerebrosidase) (Acid beta-glucosidase)	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	497	34	ba	Uncategorized enzymes	Phase III & approved biologics	311	IMLIFIDASE	enzymes	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	401	84	ba	Chimeric antibodies	Phase III & approved biologics	666	IMSIDOLIMAB	monoclonal antibodies	NA	Chimeric	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	199	84	ba	Human antibodies	Phase III & approved biologics	665	INCLACUMAB	monoclonal antibodies	Inclacumab (human mab)	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	707	85	ba	Mouse antibodies	Phase III & approved biologics	642	INDIUM IN 111 SATUMOMAB PENDETIDE	monoclonal antibodies; peptides	Satumomab pendetide (mouse mab)	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Human insulins	Phase III & approved biologics	51	INSULIN ASPART	NA	Insulin aspart	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Human insulins	Phase III & approved biologics	50	INSULIN DEGLUDEC	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Human insulins	Phase III & approved biologics	50	INSULIN DETEMIR	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Human insulins	Phase III & approved biologics	53	INSULIN GLARGINE	NA	Insulin glargine recombinant	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Human insulins	Phase III & approved biologics	51	INSULIN GLULISINE	NA	Insulin glulisine recombinant	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Human insulins	Phase III & approved biologics	51	INSULIN HUMAN	NA	Recombinant human insulin	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Human insulins	Phase III & approved biologics	51	INSULIN LISPRO	NA	Insulin lispro recombinant	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Human insulins	Phase III & approved biologics	51	INSULIN LISPRO PROTAMINE RECOMBINANT	NA	Insulin lispro protamine recombinant	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Human insulins	Phase III & approved biologics	51	INSULIN PORK	NA	Porcine insulin	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Non-human, non-murine biologics	Phase III & approved biologics	51	INSULIN PURIFIED BEEF	NA	Purified bovine insulin	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Non-human, non-murine biologics	Phase III & approved biologics	51	INSULIN PURIFIED PORK	NA	Purified porcine insulin	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Other uncategorized biologics	Phase III & approved biologics	165	INTERFERON ALFA-2B	NA	Interferon alpha-2 precursor (Interferon alpha-A) (LeIF A)	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	10	3	ba	Other uncategorized biologics	Phase III & approved biologics	167	INTERFERON ALFACON-1	NA	Interferon alpha-2 precursor (Interferon alpha-A) (LeIF A)	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Other uncategorized biologics	Phase III & approved biologics	166	INTERFERON BETA-1A	NA	Interferon beta precursor (IFN-beta) (Fibroblast interferon)	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	16	14	ba	Other uncategorized biologics	Phase III & approved biologics	165	INTERFERON BETA-1B	NA	Interferon beta precursor (IFN-beta) (Fibroblast interferon)	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Other uncategorized biologics	Phase III & approved biologics	140	INTERFERON GAMMA-1B	NA	Interferon gamma precursor (IFN-gamma) (Immune interferon)	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	603	86	ba	Uncategorized mABs	Phase III & approved biologics	663	IODINE I 124 GIRENTUXIMAB	iodine-containing contrast media; monoclonal antibodies	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	528	86	ba	Chimeric antibodies	Phase III & approved biologics	664	ISATUXIMAB	monoclonal antibodies	NA	Chimeric	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	18	7	ba	Other uncategorized biologics	Phase III & approved biologics	153	ISUNAKINRA	interleukin receptor antagonists: interleukin-1 (IL-1) receptor antagonists	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	423	86	ba	Human antibodies	Phase III & approved biologics	663	ITEPEKIMAB	monoclonal antibodies	NA	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	473	86	ba	Humanized antibodies	Phase III & approved biologics	663	ITOLIZUMAB	monoclonal antibodies	Itolizumab (humanized mab)	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	287	86	ba	Humanized antibodies	Phase III & approved biologics	664	IXEKIZUMAB	monoclonal antibodies	Ixekizumab (humanized mab)	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	92	11	ba	Non-human, non-murine biologics	Phase III & approved biologics	173	IZOKIBEP	bioengineered proteins	NA	synthetic construct	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	220	84	ba	Humanized antibodies	Phase III & approved biologics	437	LAMPALIZUMAB	ionotropic non-NMDA (N-methyl D-aspartate) glutamate receptors [AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor) and/or KA (kainite antagonist) receptors]; monoclonal antibodies	Lampalizumab (humanized mab)	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	413	84	ba	Human antibodies	Phase III & approved biologics	664	LANADELUMAB	monoclonal antibodies	NA	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Uncategorized enzymes	Phase III & approved biologics	628	LARONIDASE	enzymes	Alpha-L-iduronidase precursor	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	202	84	ba	Human antibodies	Phase III & approved biologics	671	LATOZINEMAB	monoclonal antibodies	NA	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	404	84	ba	Humanized antibodies	Phase III & approved biologics	663	LEBRIKIZUMAB	monoclonal antibodies	Lebrikizumab (humanized mab)	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	425	86	ba	Chimeric antibodies	Phase III & approved biologics	673	LECANEMAB	monoclonal antibodies	NA	Chimeric	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	390	86	ba	Human antibodies	Phase III & approved biologics	665	LEMZOPARLIMAB	monoclonal antibodies	NA	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	366	84	ba	Human antibodies	Phase III & approved biologics	663	LENZILUMAB	monoclonal antibodies	NA	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	7	7	ba	Other uncategorized biologics	Phase III & approved biologics	65	LEPIRUDIN	anticoagulants (hirudin type)	Hirudin variant-1 (Lepirudin)	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	181	84	ba	Humanized antibodies	Phase III & approved biologics	668	LERONLIMAB	monoclonal antibodies	PRO-140 (humanized mab)	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	322	84	ba	Humanized antibodies	Phase III & approved biologics	667	LIGELIZUMAB	monoclonal antibodies	Ligelizumab (humanized mab)	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	250	86	ba	Human antibodies	Phase III & approved biologics	1116	LINVOSELTAMAB	monoclonal antibodies	NA	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	348	76	ba	Humanized antibodies	Phase III & approved biologics	663	LIRENTELIMAB	monoclonal antibodies	NA	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	286	84	ba	Humanized antibodies	Phase III & approved biologics	669	LITIFILIMAB	monoclonal antibodies	NA	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	23	6	ba	Non-human, non-murine biologics	Phase III & approved biologics	44	LIXISENATIDE	peptides: exendin-4-derivatives	NA	Heloderma suspectum	<50 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	105	19	ba	Chimeric antibodies	Phase III & approved biologics	449	LONCASTUXIMAB TESIRINE	monoclonal antibodies	NA	Chimeric	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	NA	Phase III & approved biologics	335	LUSPATERCEPT	receptor molecules or membrane ligands, natural, modified or modified: transforming growth factor receptors	Luspatercept	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	200	86	ba	Human antibodies	Phase III & approved biologics	661	MAFTIVIMAB	monoclonal antibodies	NA	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	246	86	ba	Chimeric antibodies	Phase III & approved biologics	663	MAGROLIMAB	monoclonal antibodies	NA	Chimeric	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	472	84	ba	Chimeric antibodies	Phase III & approved biologics	664	MARGETUXIMAB	monoclonal antibodies	Margetuximab (chimeric mab)	Chimeric	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	152	41	ba	Human antibodies	Phase III & approved biologics	667	MARSTACIMAB	monoclonal antibodies	NA	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Other uncategorized biologics	Phase III & approved biologics	70	MECASERMIN	growth factors: insulin-like growth factors	Insulin-like growth factor IA [Precursor]	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	22	12	ba	Other uncategorized biologics	Phase III & approved biologics	334	MECASERMIN RINFABATE	growth factors: insulin-like growth factors	Insulin-like growth factor IA [Precursor]; Insulin-like growth factor-binding protein 3 [Precursor]	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	306	84	ba	Humanized antibodies	Phase III & approved biologics	655	MIRIKIZUMAB	monoclonal antibodies	NA	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	509	86	ba	Chimeric antibodies	Phase III & approved biologics	665	MIRVETUXIMAB SORAVTANSINE	monoclonal antibodies; maytansinoid derivatives	NA	Chimeric	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	504	86	ba	Chimeric antibodies	Phase III & approved biologics	667	MODOTUXIMAB	monoclonal antibodies	NA	Chimeric	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	244	84	ba	Humanized antibodies	Phase III & approved biologics	671	MOGAMULIZUMAB	monoclonal antibodies	Mogamulizumab (humanized mab)	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	667	84	ba	Humanized antibodies	Phase III & approved biologics	1333	MOSUNETUZUMAB	monoclonal antibodies	NA	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	335	84	ba	Humanized antibodies	Phase III & approved biologics	663	MOTAVIZUMAB	monoclonal antibodies	Motavizumab (humanized mab)	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	1197	65	ba	Mouse antibodies	Phase III & approved biologics	584	MOXETUMOMAB PASUDOTOX	monoclonal antibodies	Moxetumomab pasudotox (mouse mab)	Mus musculus	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	282	84	ba	Humanized antibodies	Phase III & approved biologics	670	MUPADOLIMAB	analgesics (mixed opiate receptor agonists/antagonists); monoclonal antibodies	NA	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	524	43	ba	NA	Phase III & approved biologics	663	MUROMONAB-CD3	cannabinol derivatives	Muromonab-CD3 (mouse mab)	Mus musculus	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	123	84	ba	Non-human, non-murine biologics	Phase III & approved biologics	664	NARLUMOSBART	NA	NA	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	112	30	ba	Human antibodies	Phase III & approved biologics	657	NARSOPLIMAB	monoclonal antibodies	NA	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	653	84	ba	Chimeric antibodies	Phase III & approved biologics	1327	NAVICIXIZUMAB	monoclonal antibodies	NA	Chimeric	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	564	86	ba	Chimeric antibodies	Phase III & approved biologics	660	NAXITAMAB	monoclonal antibodies	NA	Chimeric	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	152	77	ba	Human antibodies	Phase III & approved biologics	665	NECITUMUMAB	monoclonal antibodies	Necitumumab (human mab)	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Other uncategorized biologics	Phase III & approved biologics	53	NEPIDERMIN	growth factors: epidermal growth factors	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Therapeutic peptides	Phase III & approved biologics	32	NESIRITIDE	peptides: atrial natriuretic type substances	Natriuretic peptides B [Precursor]	NA	<50 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	162	21	ba	Human antibodies	Phase III & approved biologics	661	NIPOCALIMAB	monoclonal antibodies	NA	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	317	84	ba	Humanized antibodies	Phase III & approved biologics	670	NIRSEVIMAB	monoclonal antibodies	NA	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	140	44	ba	Non-human, non-murine biologics	Phase III & approved biologics	661	NISEVOKITUG	NA	NA	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	239	84	ba	Human antibodies	Phase III & approved biologics	654	NIVOLUMAB	monoclonal antibodies	Nivolumab (human mab)	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	64	25	ba	Non-human, non-murine biologics	Phase III & approved biologics	114	NOGAPENDEKIN ALFA	interleukins	NA	Homo sapiens	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	103	27	ba	Other uncategorized biologics	Phase III & approved biologics	150	NOMACOPAN	complement receptor antagonists/complement inhibitors	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	18	9	ba	Other uncategorized biologics	Phase III & approved biologics	415	NONACOG BETA PEGOL	PEGylated compounds, covalent attachment of macrogol (polyethylene glycol) polymer	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	439	91	ba	Chimeric antibodies	Phase III & approved biologics	663	OBILTOXAXIMAB	monoclonal antibodies	NA	Chimeric	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	379	84	ba	Humanized antibodies	Phase III & approved biologics	668	OBINUTUZUMAB	monoclonal antibodies	Obinutuzumab (humanized mab)	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	304	84	ba	Humanized antibodies	Phase III & approved biologics	663	OCIPERLIMAB	monoclonal antibodies	NA	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Other uncategorized biologics	Phase III & approved biologics	249	OCRIPLASMIN	plasmin proteins and derivatives	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	203	84	ba	Human antibodies	Phase III & approved biologics	668	ODESIVIMAB	monoclonal antibodies	NA	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	320	84	ba	Human antibodies	Phase III & approved biologics	671	OLARATUMAB	monoclonal antibodies	Olaratumab (human mab)	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	246	63	ba	Human antibodies	Phase III & approved biologics	663	OLECLUMAB	monoclonal antibodies	NA	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Uncategorized enzymes	Phase III & approved biologics	570	OLIPUDASE ALFA	enzymes	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	330	86	ba	Humanized antibodies	Phase III & approved biologics	661	OLOKIZUMAB	monoclonal antibodies	Olokizumab (humanized mab)	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	276	84	ba	Humanized antibodies	Phase III & approved biologics	662	OMALIZUMAB	monoclonal antibodies	Immunoglobulin G, anti-(human immunoglobulin E Fc region) (human-mouse monoclonal E25 clone pSVIE26 y-chain), disulfide with human-mouse monoclonal E25 clone pSVIE26 x-chain, dimer	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	356	84	ba	Humanized antibodies	Phase III & approved biologics	896	ONARTUZUMAB	monoclonal antibodies	Onartuzumab (humanized mab)	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	1394	53	ba	Humanized antibodies	Phase III & approved biologics	647	OPORTUZUMAB MONATOX	monoclonal antibodies	Oportuzumab monatox (humanized scFv)	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Other uncategorized biologics	Phase III & approved biologics	177	OPRELVEKIN	interleukins: interleukin-11 analogues and derivatives	Interleukin-11 precursor (IL-11) (Adipogenesis inhibitory factor)	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	357	48	ba	Chimeric antibodies	Phase III & approved biologics	665	OTELIXIZUMAB	monoclonal antibodies	Otelixizumab (chimeric and humanized mab)	Chimeric	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	168	24	ba	Human antibodies	Phase III & approved biologics	657	OTILIMAB	monoclonal antibodies	MOR-103 (human mab)	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Other uncategorized biologics	Phase III & approved biologics	141	PALIFERMIN	growth factors: fibroblast growth factors	[23-methionine]-23-163-fibroblast growth factor 7 (human clone 32/49 reduced)	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	169	86	ba	Human antibodies	Phase III & approved biologics	663	PAMREVLUMAB	monoclonal antibodies	FG-3019 (mab)	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Other uncategorized biologics	Phase III & approved biologics	84	PARATHYROID HORMONE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	194	84	ba	Human antibodies	Phase III & approved biologics	667	PATRITUMAB	monoclonal antibodies	Patritumab (human mab)	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	194	84	ba	Human antibodies	Phase III & approved biologics	667	PATRITUMAB DERUXTECAN	monoclonal antibodies; antineoplastics (camptothecin derivatives)	NA	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	209	19	ba	Uncategorized enzymes	Phase III & approved biologics	356	PEGADEMASE BOVINE	enzymes; PEGylated compounds, covalent attachment of macrogol (polyethylene glycol) polymer	Adenosine deaminase (Adenosine aminohydrolase)	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	1398	62	ba	Uncategorized enzymes	Phase III & approved biologics	408	PEGARGIMINASE	enzymes; PEGylated compounds, covalent attachment of macrogol (polyethylene glycol) polymer	Pegargiminase (pegylated arginine deiminase)	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Non-human, non-murine biologics	Phase III & approved biologics	175	PEGFILGRASTIM	PEGylated compounds, covalent attachment of macrogol (polyethylene glycol) polymer; colony-stimulating factors: granulocyte colony-stimulating factors (G-CSF)	Granulocyte colony-stimulating factor precursor (G-CSF) (Pluripoietin)	Homo sapiens	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	140	34	ba	Non-human, non-murine biologics	Phase III & approved biologics	165	PEGINTERFERON ALFA-2A	PEGylated compounds, covalent attachment of macrogol (polyethylene glycol) polymer	Interferon alpha-2 precursor (Interferon alpha-A) (LeIF A)	Homo sapiens	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Other uncategorized biologics	Phase III & approved biologics	165	PEGINTERFERON ALFA-2B	PEGylated compounds, covalent attachment of macrogol (polyethylene glycol) polymer	Interferon alpha-2 precursor (Interferon alpha-A) (LeIF A)	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	674	67	ba	Non-human, non-murine biologics	Phase III & approved biologics	298	PEGLOTICASE	enzymes; PEGylated compounds, covalent attachment of macrogol (polyethylene glycol) polymer	Tetramer alpha4 of des-(1-5)-[6-threonine,45-threonine,290-lysine,300-serine]uricase (EC 1.7.3.3, urate oxidase) from Sus scrofa (porcine), non acetylated, of which some of the lysine 6-amine residues are engaged in a carbamate linkage with a monomethylic ether of polyoxyethylene (macrogol)	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	8	8	ba	Non-human, non-murine biologics	Phase III & approved biologics	182	PEGOZAFERMIN	growth factors: fibroblast growth factors; PEGylated compounds, covalent attachment of macrogol (polyethylene glycol) polymer	NA	Homo sapiens	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	1	1	ba	Uncategorized enzymes	Phase III & approved biologics	405	PEGUNIGALSIDASE ALFA	enzymes; PEGylated compounds, covalent attachment of macrogol (polyethylene glycol) polymer	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Other uncategorized biologics	Phase III & approved biologics	165	PEGVISOMANT	PEGylated compounds, covalent attachment of macrogol (polyethylene glycol) polymer	Somatotropin precursor (Growth hormone) (GH)	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Uncategorized enzymes	Phase III & approved biologics	321	PEGZILARGINASE	enzymes; PEGylated compounds, covalent attachment of macrogol (polyethylene glycol) polymer	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	275	84	ba	Humanized antibodies	Phase III & approved biologics	665	PEMBROLIZUMAB	monoclonal antibodies	Pembrolizumab (humanized mab)	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	375	68	ba	Chimeric antibodies	Phase III & approved biologics	662	PENPULIMAB	monoclonal antibodies	NA	Chimeric	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	83	32	ba	Other uncategorized biologics	Phase III & approved biologics	22	PEXIGANAN	antimicrobial, bactericidal permeability increasing polypeptide	PEXIGANAN	NA	<50 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	326	84	ba	Humanized antibodies	Phase III & approved biologics	665	POLATUZUMAB VEDOTIN	synthetic analogs of the dolastatin series; monoclonal antibodies	Polatuzumab vedotin (humanized mab)	Humanized	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	142	84	ba	Human antibodies	Phase III & approved biologics	661	POZELIMAB	monoclonal antibodies	NA	Homo sapiens	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	8200	78	ba	Other uncategorized biologics	Phase III & approved biologics	2490	PRABOTULINUMTOXIN A	fluoroquinolone derivatives, nonantibacterial indication (e.g., antineoplastic antibiotics)	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	35	7	ba	Therapeutic peptides	Phase III & approved biologics	37	PRAMLINTIDE	peptides: amylin derivatives or mimics	PRAMLINTIDE	NA	<50 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	380	86	ba	Uncategorized mABs	Phase III & approved biologics	658	QUAVONLIMAB	monoclonal antibodies	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	803	41	ba	Mouse antibodies	Phase III & approved biologics	659	RACOTUMOMAB	monoclonal antibodies	Racotumomab (mouse mab)	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	189	61	ba	Human antibodies	Phase III & approved biologics	660	RAMUCIRUMAB	monoclonal antibodies	Ramucirumab (human mab)	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	335	84	ba	Uncategorized mABs	Phase III & approved biologics	431	RANIBIZUMAB	monoclonal antibodies	Immunoglobulin G1, anti-(human vascular endothelial growth factor) Fab fragment (human-mouse monoclonal rhuFAB V2 gamma1-chain), disulfide with human-mouse monoclonal rhuFAB V2 kappa-chain	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	192	91	ba	Uncategorized enzymes	Phase III & approved biologics	104	RANPIRNASE	enzymes	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	507	58	ba	Uncategorized enzymes	Phase III & approved biologics	301	RASBURICASE	enzymes	Uricase (Urate oxidase)	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	183	84	ba	Uncategorized mABs	Phase III & approved biologics	214	RAVULIZUMAB	monoclonal antibodies	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	4395	78	ba	Other uncategorized biologics	Phase III & approved biologics	1295	RELABOTULINUMTOXINA	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	96	71	ba	Uncategorized mABs	Phase III & approved biologics	214	RELATLIMAB	monoclonal antibodies	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	207	84	ba	Other uncategorized biologics	Phase III & approved biologics	665	REMTERNETUG	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	249	84	ba	Uncategorized mABs	Phase III & approved biologics	663	RETIFANLIMAB	monoclonal antibodies	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	61	17	ba	Uncategorized enzymes	Phase III & approved biologics	947	REVEGLUCOSIDASE ALFA	enzymes	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	3	3	ba	Other uncategorized biologics	Phase III & approved biologics	880	RILONACEPT	receptor molecules or membrane ligands, natural, modified or modified: interleukin receptors	[653-glycine][human interleukin-1 receptor accessory protein-(1-339)-peptide (extracellular domain fragment) fusion protein with human type 1 interleukin-1 receptor-(5-316)-peptide (extracellular domain fragment) fusion protein with human immunoglobulin G1-(229 C-terminal residues)-peptide (Fc fragment)], (659-659':662-662')-bisdisulfide dimer	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	222	86	ba	Human antibodies	Phase III & approved biologics	661	RILOTUMUMAB	monoclonal antibodies	Rilotumumab (human mab)	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	3790	74	ba	Other uncategorized biologics	Phase III & approved biologics	1291	RIMABOTULINUMTOXINB	fluoroquinolone derivatives, nonantibacterial indication (e.g., antineoplastic antibiotics)	Botulinum neurotoxin type B precursor (BoNT/B) (Bontoxilysin B)	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	271	86	ba	Uncategorized mABs	Phase III & approved biologics	663	RISANKIZUMAB	monoclonal antibodies	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	509	86	ba	Chimeric antibodies	Phase III & approved biologics	664	RITUXIMAB	monoclonal antibodies	Rituximab (chimeric mab)	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	170	84	ba	Uncategorized mABs	Phase III & approved biologics	661	ROCATINLIMAB	monoclonal antibodies	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	39	22	ba	Other uncategorized biologics	Phase III & approved biologics	269	ROMIPLOSTIM	colony-stimulating factors	L-methionyl[human immunogloblin heavy constant gamma 1-(227 C-terminal residues)-peptide (Fc fragment)] fusion protein with 41 amino acids peptide, (7-7':10,10')-bisdisulfide dimer	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	148	40	ba	Uncategorized mABs	Phase III & approved biologics	662	ROMLUSEVIMAB	monoclonal antibodies	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	297	84	ba	Humanized antibodies	Phase III & approved biologics	663	ROMOSOZUMAB	monoclonal antibodies	Romosozumab (humanized mab)	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	337	68	ba	Uncategorized mABs	Phase III & approved biologics	665	ROSMANTUZUMAB	monoclonal antibodies	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	291	86	ba	Uncategorized mABs	Phase III & approved biologics	214	ROVALPITUZUMAB TESIRINE	monoclonal antibodies	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	398	86	ba	Uncategorized mABs	Phase III & approved biologics	663	ROZANOLIXIZUMAB	monoclonal antibodies	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	285	84	ba	Uncategorized mABs	Phase III & approved biologics	662	SABATOLIMAB	monoclonal antibodies	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	338	84	ba	Uncategorized mABs	Phase III & approved biologics	665	SACITUZUMAB GOVITECAN	monoclonal antibodies; antineoplastics (camptothecin derivatives)	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	39	17	ba	Other uncategorized biologics	Phase III & approved biologics	127	SARGRAMOSTIM	colony-stimulating factors: granulocyte macrophage colony-stimulating factors (GM-CSF); colony-stimulating factors: macrophage colony-stimulating factors (M-CSF)	Granulocyte-macrophage colony-stimulating factor [Precursor]	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	415	86	ba	Human antibodies	Phase III & approved biologics	660	SARILUMAB	antiviral (arildone derivatives); monoclonal antibodies	Sarilumab (human mab)	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	226	84	ba	Uncategorized mABs	Phase III & approved biologics	664	SASANLIMAB	monoclonal antibodies	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	233	43	ba	Uncategorized mABs	Phase III & approved biologics	657	SATRALIZUMAB	monoclonal antibodies	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Uncategorized enzymes	Phase III & approved biologics	378	SEBELIPASE ALFA	enzymes	Sebelipase alfa	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Other uncategorized biologics	Phase III & approved biologics	27	SECRETIN SYNTHETIC HUMAN	retinol derivatives	Secretin precursor	NA	<50 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	27	12	ba	Other uncategorized biologics	Phase III & approved biologics	27	SECRETIN SYNTHETIC PORCINE	retinol derivatives	Secretin [Precursor] [Fragment]	NA	<50 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	356	86	ba	Human antibodies	Phase III & approved biologics	672	SECUKINUMAB	monoclonal antibodies	Secukinumab (human mab)	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	48	23	ba	Non-human, non-murine biologics	Phase III & approved biologics	31	SEMAGLUTIDE	peptides: glucagon-like peptide (GLP) analogs	NA	NA	<50 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	372	86	ba	Uncategorized mABs	Phase III & approved biologics	666	SEMZUVOLIMAB	monoclonal antibodies	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	9	9	ba	Therapeutic peptides	Phase III & approved biologics	39	SERACTIDE ACETATE	peptides: synthetic corticotropins	Corticotropin-lipotropin precursor (Pro-opiomelanocortin) (POMC)	NA	<50 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Other uncategorized biologics	Phase III & approved biologics	53	SERELAXIN	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Other uncategorized biologics	Phase III & approved biologics	29	SERMORELIN ACETATE	prehormones or hormone-release stimulating peptides: growth hormone-release stimulating peptides	Somatoliberin [Precursor]	NA	<50 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	556	86	ba	Chimeric antibodies	Phase III & approved biologics	662	SILTUXIMAB	monoclonal antibodies	Siltuximab (chimeric mab)	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	8	4	ba	Other uncategorized biologics	Phase III & approved biologics	1440	SIMOCTOCOG ALFA	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	334	84	ba	Uncategorized mABs	Phase III & approved biologics	661	SINTILIMAB	monoclonal antibodies	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	402	84	ba	Human antibodies	Phase III & approved biologics	662	SIRUKUMAB	monoclonal antibodies	Sirukumab (human mab)	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	103	32	ba	Uncategorized mABs	Phase III & approved biologics	664	SOCAZOLIMAB	monoclonal antibodies	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	273	84	ba	Humanized antibodies	Phase III & approved biologics	660	SOLANEZUMAB	monoclonal antibodies	Solanezumab (humanized mab)	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Other uncategorized biologics	Phase III & approved biologics	192	SOMATREM	growth hormone derivatives	Somatotropin precursor (Growth hormone) (GH)	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Uncategorized atropines	Phase III & approved biologics	191	SOMATROPIN	tricyclic compounds; growth hormone derivatives; atropine derivatives	Somatotropin precursor (Growth hormone) (GH)	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	21	8	ba	Other uncategorized biologics	Phase III & approved biologics	1250	SOMAVARATAN	growth hormone derivatives	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	11	11	ba	Other uncategorized biologics	Phase III & approved biologics	344	SOTATERCEPT	receptor molecules or membrane ligands, natural, modified or modified: transforming growth factor receptors	Sotatercept (immunoadhesin)	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	153	84	ba	Uncategorized mABs	Phase III & approved biologics	663	SPARTALIZUMAB	monoclonal antibodies	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	401	86	ba	Uncategorized mABs	Phase III & approved biologics	664	SPESOLIMAB	monoclonal antibodies	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	390	84	ba	Other uncategorized biologics	Phase III & approved biologics	660	STAPOKIBART	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	277	84	ba	Uncategorized mABs	Phase III & approved biologics	667	SUPTAVUMAB	monoclonal antibodies	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	355	86	ba	Uncategorized mABs	Phase III & approved biologics	661	SUTIMLIMAB	monoclonal antibodies	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	129	84	ba	Uncategorized mABs	Phase III & approved biologics	665	SUVRATOXUMAB	monoclonal antibodies	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	180	84	ba	Human antibodies	Phase III & approved biologics	664	TABALUMAB	monoclonal antibodies	Tabalumab (human mab)	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Other uncategorized biologics	Phase III & approved biologics	165	TADEKINIG ALFA	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	331	86	ba	Uncategorized mABs	Phase III & approved biologics	670	TAFASITAMAB	monoclonal antibodies	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	880	56	ba	Other uncategorized biologics	Phase III & approved biologics	524	TAGRAXOFUSP	fusion proteins	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	53	22	ba	Other uncategorized biologics	Phase III & approved biologics	692	TALACTOFERRIN ALFA	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	193	48	ba	Other uncategorized biologics	Phase III & approved biologics	340	TALDEFGROBEP ALFA	bioengineered proteins	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	723	86	ba	Uncategorized mABs	Phase III & approved biologics	1326	TALQUETAMAB	monoclonal antibodies	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	346	84	ba	Uncategorized mABs	Phase III & approved biologics	667	TARCOCIMAB TEDROMER	monoclonal antibodies; polymers	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	277	22	ba	Uncategorized mABs	Phase III & approved biologics	950	TARLATAMAB	monoclonal antibodies	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Other uncategorized biologics	Phase III & approved biologics	157	TASONERMIN	growth factors: tumor necrosis factors	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	325	45	ba	Other uncategorized biologics	Phase III & approved biologics	695	TEBENTAFUSP	fusion proteins	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Therapeutic peptides	Phase III & approved biologics	27	TECEMOTIDE	peptides	Tecemotide	NA	<50 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Other uncategorized biologics	Phase III & approved biologics	585	TECHNETIUM TC 99M ALBUMIN	NA	Serum albumin precursor	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Other uncategorized biologics	Phase III & approved biologics	585	TECHNETIUM TC 99M ALBUMIN AGGREGATED	NA	Serum albumin precursor	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	1228	85	ba	Mouse antibodies	Phase III & approved biologics	655	TECHNETIUM TC 99M ARCITUMOMAB	monoclonal antibodies	Arcitumomab 99Tc (mouse Fab')	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	300	29	ba	Uncategorized mABs	Phase III & approved biologics	1329	TECLISTAMAB	monoclonal antibodies	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Non-human, non-murine biologics	Phase III & approved biologics	33	TEDUGLUTIDE	peptides: glucagon-like peptide (GLP) analogs	TEDUGLUTIDE	NA	<50 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	326	84	ba	Humanized antibodies	Phase III & approved biologics	662	TEPLIZUMAB	monoclonal antibodies	Teplizumab (humanized mab)	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	181	26	ba	Human antibodies	Phase III & approved biologics	663	TEPROTUMUMAB	monoclonal antibodies	Teprotumumab (human mab)	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Therapeutic peptides	Phase III & approved biologics	34	TERIPARATIDE ACETATE	peptides: parathyroid hormone related peptide	Parathyroid hormone precursor (Parathyrin) (PTH)	NA	<50 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Therapeutic peptides	Phase III & approved biologics	16	TERTOMOTIDE	peptides	NA	NA	<50 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	84	18	ba	Other uncategorized biologics	Phase III & approved biologics	44	TESAMORELIN	prehormones or hormone-release stimulating peptides: growth hormone-release stimulating peptides	(3E)-hex-3-enoylsomatoliberin (human GHRH)	NA	<50 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Other uncategorized biologics	Phase III & approved biologics	44	TESAMORELIN ACETATE	prehormones or hormone-release stimulating peptides: growth hormone-release stimulating peptides	NA	NA	<50 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	107	17	ba	Uncategorized mABs	Phase III & approved biologics	662	TEZEPELUMAB	monoclonal antibodies	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Other uncategorized biologics	Phase III & approved biologics	498	THROMBOMODULIN ALFA	NA	Thrombomodulin alfa	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Other uncategorized biologics	Phase III & approved biologics	28	THYMALFASIN	NA	THYMALFASIN	NA	<50 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	122	40	ba	Uncategorized atropines	Phase III & approved biologics	208	THYROTROPIN	tricyclic compounds; atropine derivatives	Thyrotropin beta chain precursor (Thyroid-stimulating hormone beta subunit) (TSH-beta)	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Uncategorized atropines	Phase III & approved biologics	210	THYROTROPIN ALFA	tricyclic compounds; atropine derivatives	Thyrotropin beta chain precursor (Thyroid-stimulating hormone beta subunit) (TSH-beta)	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Other uncategorized biologics	Phase III & approved biologics	277	TIFACOGIN	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	339	84	ba	Humanized antibodies	Phase III & approved biologics	662	TIGATUZUMAB	monoclonal antibodies	Tigatuzumab (humanized mab)	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Other uncategorized biologics	Phase III & approved biologics	43	TIMBETASIN ACETATE	NA	NA	NA	<50 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	267	84	ba	Uncategorized mABs	Phase III & approved biologics	676	TIRAGOLUMAB	monoclonal antibodies	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	300	86	ba	Uncategorized mABs	Phase III & approved biologics	659	TISLELIZUMAB	monoclonal antibodies	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	185	86	ba	Uncategorized mABs	Phase III & approved biologics	662	TISOTUMAB VEDOTIN	synthetic analogs of the dolastatin series; monoclonal antibodies	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	282	84	ba	Uncategorized mABs	Phase III & approved biologics	669	TIXAGEVIMAB	monoclonal antibodies	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	463	86	ba	Other uncategorized biologics	Phase III & approved biologics	664	TOMINERSEN	antisense oligonucleotides: neurologic indications	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	543	39	ba	Other uncategorized biologics	Phase III & approved biologics	476	TOPSALYSIN	anti-inflammatory agents (salicylic acid derivatives)	Pore-forming protein (synthetic proaerolysin) fusion protein with prostate-specific antigen (human)	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	247	86	ba	Uncategorized mABs	Phase III & approved biologics	671	TORIPALIMAB	monoclonal antibodies	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	473	68	ba	Mouse antibodies	Phase III & approved biologics	657	TOSITUMOMAB	monoclonal antibodies	Tositumomab (mouse mab)	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	129	21	ba	Uncategorized mABs	Phase III & approved biologics	668	TOZORAKIMAB	monoclonal antibodies	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	61	6	ba	Human antibodies	Phase III & approved biologics	663	TRALOKINUMAB	monoclonal antibodies	Tralokinumab (human mab)	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	257	84	ba	Uncategorized mABs	Phase III & approved biologics	665	TRASTUZUMAB	monoclonal antibodies	Immunoglobulin G1-kappa, anti-[Homo sapiens ERBB2 (epidermal growth factor receptor 2, HER-2, p185c-erbB2, NEU, EGFR2)], humanized monoclonal antibody conjugated to maytansinoid DM1; gamma1 heavy chain (1-449) [humanized VH (Homo sapiens IGHV3-66*01 (81.60%) -(IGHD)-IGHJ6*01 T123>L) [8.8.13] (1-120) - Homo sapiens IGHG1*03 (121-449) CH1 R120>K], (223-214')-disulfide with kappa light chain (1’-214’) [humanized V-KAPPA (Homo sapiens IGKV1-39*01 (86.30%) -IGKJ1*01) [6.3.9] (1'-107') - Homo sapiens IGKC*01 (108'-214')]; (229-229"""":232-232"""")-bisdisulfide dimer; conjugated, on an average of 3 to 4 lysyl, to maytansinoid DM1 via a succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) linker.	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	257	84	ba	Uncategorized mABs	Phase III & approved biologics	664	TRASTUZUMAB DERUXTECAN	monoclonal antibodies; antineoplastics (camptothecin derivatives)	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	257	84	ba	Uncategorized mABs	Phase III & approved biologics	663	TRASTUZUMAB DUOCARMAZINE	monoclonal antibodies	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	257	84	ba	Humanized antibodies	Phase III & approved biologics	663	TRASTUZUMAB EMTANSINE	monoclonal antibodies; maytansinoid derivatives	Trastuzumab Emtansine (humanized mab)	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	257	84	ba	Uncategorized mABs	Phase III & approved biologics	664	TRASTUZUMAB VEDOTIN	synthetic analogs of the dolastatin series; monoclonal antibodies	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	13	4	ba	Other uncategorized biologics	Phase III & approved biologics	287	TREBANANIB	angiogenesis inhibitors	Trebananib (mab)	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Other uncategorized biologics	Phase III & approved biologics	415	TRENONACOG ALFA	NA	Trenonacog alfa	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Other uncategorized biologics	Phase III & approved biologics	1445	TUROCTOCOG ALFA	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	357	86	ba	Uncategorized mABs	Phase III & approved biologics	663	TUSAMITAMAB RAVTANSINE	monoclonal antibodies; maytansinoid derivatives	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	497	86	ba	Uncategorized mABs	Phase III & approved biologics	661	UBLITUXIMAB	monoclonal antibodies	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Therapeutic peptides	Phase III & approved biologics	32	ULARITIDE	peptides: atrial natriuretic type substances	ULARITIDE	NA	<50 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	478	84	ba	Other uncategorized biologics	Phase III & approved biologics	660	UMESOLERBART	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	1	1	ba	Uncategorized enzymes	Phase III & approved biologics	275	UROKINASE	enzymes	Urokinase-type plasminogen activator precursor (uPA) (U-plasminogen activator)	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	96	20	ba	Uncategorized mABs	Phase III & approved biologics	655	UTOMILUMAB	monoclonal antibodies	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	82	37	ba	Other uncategorized biologics	Phase III & approved biologics	406	VATREPTACOG ALFA (ACTIVATED)	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	329	84	ba	Humanized antibodies	Phase III & approved biologics	670	VEDOLIZUMAB	monoclonal antibodies	Vedolizumab (humanized mab)	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Uncategorized enzymes	Phase III & approved biologics	497	VELAGLUCERASE ALFA	enzymes	human glucosylceramidase (EC 3.2.1.45 or beta-glucocerebrosidase), glycoform alpha	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Uncategorized enzymes	Phase III & approved biologics	962	VELMANASE ALFA	enzymes	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	273	86	ba	Uncategorized mABs	Phase III & approved biologics	663	VIBOSTOLIMAB	monoclonal antibodies	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	115	50	ba	Uncategorized enzymes	Phase III & approved biologics	240	VONAPANITASE	enzymes	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Therapeutic peptides	Phase III & approved biologics	39	VOSORITIDE	peptides: atrial natriuretic type substances	NA	NA	<50 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	348	86	ba	Uncategorized mABs	Phase III & approved biologics	664	YTTRIUM Y 90 CLIVATUZUMAB TETRAXETAN	monoclonal antibodies; chelating agents	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	595	84	ba	Uncategorized mABs	Phase III & approved biologics	1145	ZANIDATAMAB	monoclonal antibodies	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	1	1	ba	Therapeutic peptides	Phase III & approved biologics	25	ZICONOTIDE	peptides	NA	NA	<50 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Therapeutic peptides	Phase III & approved biologics	25	ZICONOTIDE ACETATE	peptides	Ziconotide acetate	NA	<50 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	336	86	ba	Other uncategorized biologics	Phase III & approved biologics	662	ZIGAKIBART	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	194	33	ba	Uncategorized mABs	Phase III & approved biologics	666	ZIMBERELIMAB	monoclonal antibodies	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Other uncategorized biologics	Phase III & approved biologics	204	ZINPENTRAXIN ALFA	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	312	86	ba	Chimeric antibodies	Phase III & approved biologics	668	ZOLBETUXIMAB	monoclonal antibodies	Claudiximab (chimeric mab)	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	281	33	ba	Murine secreted proteins	Murine secreted proteins	310	AIMP1_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	191	49	ba	Murine secreted proteins	Murine secreted proteins	127	ALKL1_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	159	29	ba	Murine secreted proteins	Murine secreted proteins	151	ALKL2_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	233	37	ba	Murine secreted proteins	Murine secreted proteins	248	AREG_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	478	78	ba	Murine secreted proteins	Murine secreted proteins	991	BMP1_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	275	40	ba	Murine secreted proteins	Murine secreted proteins	421	BMP10_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	1047	83	ba	Murine secreted proteins	Murine secreted proteins	392	BMP15_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	437	39	ba	Murine secreted proteins	Murine secreted proteins	468	BMP3_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	15	5	ba	Murine secreted proteins	Murine secreted proteins	408	BMP4_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	197	40	ba	Murine secreted proteins	Murine secreted proteins	452	BMP5_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	130	16	ba	Murine secreted proteins	Murine secreted proteins	510	BMP6_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	259	54	ba	Murine secreted proteins	Murine secreted proteins	430	BMP7_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	399	61	ba	Murine secreted proteins	Murine secreted proteins	399	BMP8A_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	680	50	ba	Murine secreted proteins	Murine secreted proteins	399	BMP8B_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	113	44	ba	Murine secreted proteins	Murine secreted proteins	326	C1QT4_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	58	18	ba	Murine secreted proteins	Murine secreted proteins	133	CC21A_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	65	18	ba	Murine secreted proteins	Murine secreted proteins	133	CC21B_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	65	18	ba	Murine secreted proteins	Murine secreted proteins	133	CC21C_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	84	23	ba	Murine secreted proteins	Murine secreted proteins	92	CCL1_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	160	28	ba	Murine secreted proteins	Murine secreted proteins	97	CCL11_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	207	33	ba	Murine secreted proteins	Murine secreted proteins	104	CCL12_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	422	79	ba	Murine secreted proteins	Murine secreted proteins	93	CCL17_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	252	36	ba	Murine secreted proteins	Murine secreted proteins	108	CCL19_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	414	83	ba	Murine secreted proteins	Murine secreted proteins	148	CCL2_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	224	46	ba	Murine secreted proteins	Murine secreted proteins	97	CCL20_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	111	15	ba	Murine secreted proteins	Murine secreted proteins	92	CCL22_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	155	20	ba	Murine secreted proteins	Murine secreted proteins	119	CCL24_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	437	68	ba	Murine secreted proteins	Murine secreted proteins	144	CCL25_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	468	42	ba	Murine secreted proteins	Murine secreted proteins	120	CCL27_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	106	16	ba	Murine secreted proteins	Murine secreted proteins	130	CCL28_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	157	22	ba	Murine secreted proteins	Murine secreted proteins	92	CCL3_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	163	20	ba	Murine secreted proteins	Murine secreted proteins	92	CCL4_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	306	60	ba	Murine secreted proteins	Murine secreted proteins	91	CCL5_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	190	27	ba	Murine secreted proteins	Murine secreted proteins	116	CCL6_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	17	13	ba	Murine secreted proteins	Murine secreted proteins	97	CCL7_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	239	53	ba	Murine secreted proteins	Murine secreted proteins	97	CCL8_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	191	35	ba	Murine secreted proteins	Murine secreted proteins	122	CCL9_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	605	75	ba	Murine secreted proteins	Murine secreted proteins	260	CD40L_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	343	34	ba	Murine secreted proteins	Murine secreted proteins	272	CER1_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	239	36	ba	Murine secreted proteins	Murine secreted proteins	152	CKLF_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	460	49	ba	Murine secreted proteins	Murine secreted proteins	184	CKLF3_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	366	47	ba	Murine secreted proteins	Murine secreted proteins	156	CKLF5_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	195	21	ba	Murine secreted proteins	Murine secreted proteins	167	CKLF7_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	282	54	ba	Murine secreted proteins	Murine secreted proteins	173	CKLF8_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	53	24	ba	Murine secreted proteins	Murine secreted proteins	225	CLCF1_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	904	83	ba	Murine secreted proteins	Murine secreted proteins	169	CLF2A_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	796	56	ba	Murine secreted proteins	Murine secreted proteins	210	CLF2B_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	561	43	ba	Murine secreted proteins	Murine secreted proteins	552	CSF1_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	384	70	ba	Murine secreted proteins	Murine secreted proteins	141	CSF2_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	534	68	ba	Murine secreted proteins	Murine secreted proteins	208	CSF3_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	588	40	ba	Murine secreted proteins	Murine secreted proteins	203	CTF1_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	784	62	ba	Murine secreted proteins	Murine secreted proteins	204	CTF2_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	269	49	ba	Murine secreted proteins	Murine secreted proteins	100	CXCL2_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	270	42	ba	Murine secreted proteins	Murine secreted proteins	100	CXCL3_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	461	50	ba	Murine secreted proteins	Murine secreted proteins	132	CXCL5_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	35	10	ba	Murine secreted proteins	Murine secreted proteins	126	CXCL9_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	184	33	ba	Murine secreted proteins	Murine secreted proteins	98	CXL10_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	300	36	ba	Murine secreted proteins	Murine secreted proteins	100	CXL11_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	205	36	ba	Murine secreted proteins	Murine secreted proteins	109	CXL13_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	151	40	ba	Murine secreted proteins	Murine secreted proteins	99	CXL14_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	230	64	ba	Murine secreted proteins	Murine secreted proteins	167	CXL15_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	295	36	ba	Murine secreted proteins	Murine secreted proteins	246	CXL16_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	25	8	ba	Murine secreted proteins	Murine secreted proteins	391	EDA_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	517	88	ba	Murine secreted proteins	Murine secreted proteins	235	FAM3B_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	388	42	ba	Murine secreted proteins	Murine secreted proteins	232	FLT3L_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	639	65	ba	Murine secreted proteins	Murine secreted proteins	558	G6PI_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	403	36	ba	Murine secreted proteins	Murine secreted proteins	357	GDF1_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	727	48	ba	Murine secreted proteins	Murine secreted proteins	476	GDF10_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Murine secreted proteins	Murine secreted proteins	405	GDF11_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	664	79	ba	Murine secreted proteins	Murine secreted proteins	303	GDF15_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	509	49	ba	Murine secreted proteins	Murine secreted proteins	428	GDF2_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	971	73	ba	Murine secreted proteins	Murine secreted proteins	366	GDF3_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	171	29	ba	Murine secreted proteins	Murine secreted proteins	495	GDF5_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	220	30	ba	Murine secreted proteins	Murine secreted proteins	454	GDF6_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	577	44	ba	Murine secreted proteins	Murine secreted proteins	461	GDF7_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	414	68	ba	Murine secreted proteins	Murine secreted proteins	376	GDF8_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	623	50	ba	Murine secreted proteins	Murine secreted proteins	441	GDF9_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	29	8	ba	Murine secreted proteins	Murine secreted proteins	78	GP15L_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	6	4	ba	Murine secreted proteins	Murine secreted proteins	184	GREM1_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	86	19	ba	Murine secreted proteins	Murine secreted proteins	168	GREM2_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	292	23	ba	Murine secreted proteins	Murine secreted proteins	589	GRN_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	368	67	ba	Murine secreted proteins	Murine secreted proteins	96	GROA_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	101	28	ba	Murine secreted proteins	Murine secreted proteins	156	I36RA_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	653	64	ba	Murine secreted proteins	Murine secreted proteins	189	IFNA1_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	714	64	ba	Murine secreted proteins	Murine secreted proteins	190	IFNA2_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	547	69	ba	Murine secreted proteins	Murine secreted proteins	186	IFNA4_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	720	64	ba	Murine secreted proteins	Murine secreted proteins	189	IFNA5_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	728	68	ba	Murine secreted proteins	Murine secreted proteins	189	IFNA6_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	731	71	ba	Murine secreted proteins	Murine secreted proteins	190	IFNA7_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	648	65	ba	Murine secreted proteins	Murine secreted proteins	190	IFNA9_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	678	69	ba	Murine secreted proteins	Murine secreted proteins	190	IFNAB_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	649	64	ba	Murine secreted proteins	Murine secreted proteins	189	IFNAC_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	570	84	ba	Murine secreted proteins	Murine secreted proteins	189	IFNAD_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	893	49	ba	Murine secreted proteins	Murine secreted proteins	182	IFNB_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	614	61	ba	Murine secreted proteins	Murine secreted proteins	192	IFNE_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	466	34	ba	Murine secreted proteins	Murine secreted proteins	155	IFNG_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	855	73	ba	Murine secreted proteins	Murine secreted proteins	199	IFNK_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	252	25	ba	Murine secreted proteins	Murine secreted proteins	193	IFNL2_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	284	36	ba	Murine secreted proteins	Murine secreted proteins	193	IFNL3_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	485	50	ba	Murine secreted proteins	Murine secreted proteins	178	IL10_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	366	41	ba	Murine secreted proteins	Murine secreted proteins	199	IL11_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	701	80	ba	Murine secreted proteins	Murine secreted proteins	215	IL12A_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	423	37	ba	Murine secreted proteins	Murine secreted proteins	335	IL12B_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	257	25	ba	Murine secreted proteins	Murine secreted proteins	131	IL13_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	370	51	ba	Murine secreted proteins	Murine secreted proteins	162	IL15_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	1143	61	ba	Murine secreted proteins	Murine secreted proteins	1322	IL16_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	438	60	ba	Murine secreted proteins	Murine secreted proteins	158	IL17_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	184	41	ba	Murine secreted proteins	Murine secreted proteins	180	IL17B_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	190	31	ba	Murine secreted proteins	Murine secreted proteins	194	IL17C_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	218	36	ba	Murine secreted proteins	Murine secreted proteins	161	IL17F_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	332	39	ba	Murine secreted proteins	Murine secreted proteins	192	IL18_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	521	55	ba	Murine secreted proteins	Murine secreted proteins	176	IL19_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	693	56	ba	Murine secreted proteins	Murine secreted proteins	270	IL1A_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	436	83	ba	Murine secreted proteins	Murine secreted proteins	269	IL1B_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	282	50	ba	Murine secreted proteins	Murine secreted proteins	152	IL1FA_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	476	35	ba	Murine secreted proteins	Murine secreted proteins	169	IL2_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	710	68	ba	Murine secreted proteins	Murine secreted proteins	176	IL20_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	421	62	ba	Murine secreted proteins	Murine secreted proteins	146	IL21_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	396	70	ba	Murine secreted proteins	Murine secreted proteins	179	IL22_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	465	70	ba	Murine secreted proteins	Murine secreted proteins	179	IL22B_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	669	90	ba	Murine secreted proteins	Murine secreted proteins	196	IL23A_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	926	80	ba	Murine secreted proteins	Murine secreted proteins	181	IL24_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	157	46	ba	Murine secreted proteins	Murine secreted proteins	169	IL25_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	682	61	ba	Murine secreted proteins	Murine secreted proteins	234	IL27A_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	682	79	ba	Murine secreted proteins	Murine secreted proteins	228	IL27B_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	359	67	ba	Murine secreted proteins	Murine secreted proteins	166	IL3_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	248	35	ba	Murine secreted proteins	Murine secreted proteins	163	IL31_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	385	42	ba	Murine secreted proteins	Murine secreted proteins	266	IL33_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	475	50	ba	Murine secreted proteins	Murine secreted proteins	235	IL34_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	254	32	ba	Murine secreted proteins	Murine secreted proteins	160	IL36A_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	438	45	ba	Murine secreted proteins	Murine secreted proteins	183	IL36B_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	249	39	ba	Murine secreted proteins	Murine secreted proteins	164	IL36G_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	452	56	ba	Murine secreted proteins	Murine secreted proteins	140	IL4_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	656	82	ba	Murine secreted proteins	Murine secreted proteins	252	IL40_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	334	41	ba	Murine secreted proteins	Murine secreted proteins	133	IL5_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	411	32	ba	Murine secreted proteins	Murine secreted proteins	211	IL6_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	527	67	ba	Murine secreted proteins	Murine secreted proteins	154	IL7_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	259	38	ba	Murine secreted proteins	Murine secreted proteins	144	IL9_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	416	43	ba	Murine secreted proteins	Murine secreted proteins	368	LFTY1_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	435	37	ba	Murine secreted proteins	Murine secreted proteins	368	LFTY2_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	418	41	ba	Murine secreted proteins	Murine secreted proteins	203	LIF_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	26	8	ba	Murine secreted proteins	Murine secreted proteins	115	MIF_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	53	12	ba	Murine secreted proteins	Murine secreted proteins	139	MSMP_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	186	48	ba	Murine secreted proteins	Murine secreted proteins	491	NAMPT_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	516	65	ba	Murine secreted proteins	Murine secreted proteins	354	NODAL_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	788	46	ba	Murine secreted proteins	Murine secreted proteins	263	ONCM_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	261	77	ba	Murine secreted proteins	Murine secreted proteins	294	OSTP_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	321	37	ba	Murine secreted proteins	Murine secreted proteins	182	PGRP1_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	289	66	ba	Murine secreted proteins	Murine secreted proteins	105	PLF4_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	124	39	ba	Murine secreted proteins	Murine secreted proteins	93	SDF1_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	416	59	ba	Murine secreted proteins	Murine secreted proteins	104	SG3A1_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	34	7	ba	Murine secreted proteins	Murine secreted proteins	110	SLUR1_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Murine secreted proteins	Murine secreted proteins	132	TAFA5_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	617	42	ba	Murine secreted proteins	Murine secreted proteins	309	TN13B_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	490	55	ba	Murine secreted proteins	Murine secreted proteins	291	TNF10_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	507	69	ba	Murine secreted proteins	Murine secreted proteins	316	TNF11_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	278	58	ba	Murine secreted proteins	Murine secreted proteins	249	TNF12_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	372	44	ba	Murine secreted proteins	Murine secreted proteins	241	TNF13_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	424	51	ba	Murine secreted proteins	Murine secreted proteins	239	TNF14_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	367	33	ba	Murine secreted proteins	Murine secreted proteins	252	TNF15_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	476	68	ba	Murine secreted proteins	Murine secreted proteins	173	TNF18_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	394	49	ba	Murine secreted proteins	Murine secreted proteins	235	TNFA_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	573	68	ba	Murine secreted proteins	Murine secreted proteins	202	TNFB_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	327	31	ba	Murine secreted proteins	Murine secreted proteins	306	TNFC_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	516	67	ba	Murine secreted proteins	Murine secreted proteins	198	TNFL4_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	214	20	ba	Murine secreted proteins	Murine secreted proteins	279	TNFL6_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	708	44	ba	Murine secreted proteins	Murine secreted proteins	239	TNFL8_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	537	41	ba	Murine secreted proteins	Murine secreted proteins	309	TNFL9_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	643	40	ba	Murine secreted proteins	Murine secreted proteins	356	TPO_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	195	30	ba	Murine secreted proteins	Murine secreted proteins	140	TSLP_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	339	32	ba	Murine secreted proteins	Murine secreted proteins	395	X3CL1_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	317	57	ba	Murine secreted proteins	Murine secreted proteins	114	XCL1_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	222	73	ba	Murine secreted proteins	Murine secreted proteins	198	ALR_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	233	37	ba	Murine secreted proteins	Murine secreted proteins	248	AREG_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	240	59	ba	Murine secreted proteins	Murine secreted proteins	224	ARTN_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	5	5	ba	Murine secreted proteins	Murine secreted proteins	249	BDNF_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	478	78	ba	Murine secreted proteins	Murine secreted proteins	991	BMP1_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	275	40	ba	Murine secreted proteins	Murine secreted proteins	421	BMP10_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	1047	83	ba	Murine secreted proteins	Murine secreted proteins	392	BMP15_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	432	81	ba	Murine secreted proteins	Murine secreted proteins	394	BMP2_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	437	39	ba	Murine secreted proteins	Murine secreted proteins	468	BMP3_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	15	5	ba	Murine secreted proteins	Murine secreted proteins	408	BMP4_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	197	40	ba	Murine secreted proteins	Murine secreted proteins	452	BMP5_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	130	16	ba	Murine secreted proteins	Murine secreted proteins	510	BMP6_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	259	54	ba	Murine secreted proteins	Murine secreted proteins	430	BMP7_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	680	50	ba	Murine secreted proteins	Murine secreted proteins	399	BMP8B_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	90	19	ba	Murine secreted proteins	Murine secreted proteins	177	BTC_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	184	28	ba	Murine secreted proteins	Murine secreted proteins	354	CCN3_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	141	44	ba	Murine secreted proteins	Murine secreted proteins	354	CCN6_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	313	29	ba	Murine secreted proteins	Murine secreted proteins	260	CD320_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	308	45	ba	Murine secreted proteins	Murine secreted proteins	187	CDNF_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	407	56	ba	Murine secreted proteins	Murine secreted proteins	328	CLC11_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	437	48	ba	Murine secreted proteins	Murine secreted proteins	198	CNTF_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	561	43	ba	Murine secreted proteins	Murine secreted proteins	552	CSF1_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	384	70	ba	Murine secreted proteins	Murine secreted proteins	141	CSF2_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	534	68	ba	Murine secreted proteins	Murine secreted proteins	208	CSF3_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	1742	63	ba	Murine secreted proteins	Murine secreted proteins	1217	EGF_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	314	77	ba	Murine secreted proteins	Murine secreted proteins	152	EPGN_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	150	20	ba	Murine secreted proteins	Murine secreted proteins	162	EREG_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	405	40	ba	Murine secreted proteins	Murine secreted proteins	493	FBLN3_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	71	22	ba	Murine secreted proteins	Murine secreted proteins	155	FGF1_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	157	28	ba	Murine secreted proteins	Murine secreted proteins	209	FGF10_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	47	15	ba	Murine secreted proteins	Murine secreted proteins	225	FGF11_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Murine secreted proteins	Murine secreted proteins	243	FGF12_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	10	10	ba	Murine secreted proteins	Murine secreted proteins	247	FGF14_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	795	51	ba	Murine secreted proteins	Murine secreted proteins	218	FGF15_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Murine secreted proteins	Murine secreted proteins	207	FGF16_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Murine secreted proteins	Murine secreted proteins	216	FGF17_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	17	8	ba	Murine secreted proteins	Murine secreted proteins	207	FGF18_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	77	30	ba	Murine secreted proteins	Murine secreted proteins	154	FGF2_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	15	10	ba	Murine secreted proteins	Murine secreted proteins	211	FGF20_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	354	54	ba	Murine secreted proteins	Murine secreted proteins	210	FGF21_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	504	57	ba	Murine secreted proteins	Murine secreted proteins	162	FGF22_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	572	47	ba	Murine secreted proteins	Murine secreted proteins	251	FGF23_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	122	28	ba	Murine secreted proteins	Murine secreted proteins	245	FGF3_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	488	62	ba	Murine secreted proteins	Murine secreted proteins	202	FGF4_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	134	22	ba	Murine secreted proteins	Murine secreted proteins	264	FGF5_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	292	41	ba	Murine secreted proteins	Murine secreted proteins	208	FGF6_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	238	68	ba	Murine secreted proteins	Murine secreted proteins	194	FGF7_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	45	19	ba	Murine secreted proteins	Murine secreted proteins	268	FGF8_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	7	5	ba	Murine secreted proteins	Murine secreted proteins	208	FGF9_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	639	65	ba	Murine secreted proteins	Murine secreted proteins	558	G6PI_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	403	36	ba	Murine secreted proteins	Murine secreted proteins	357	GDF1_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	727	48	ba	Murine secreted proteins	Murine secreted proteins	476	GDF10_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ba	Murine secreted proteins	Murine secreted proteins	405	GDF11_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	509	49	ba	Murine secreted proteins	Murine secreted proteins	428	GDF2_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	971	73	ba	Murine secreted proteins	Murine secreted proteins	366	GDF3_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	171	29	ba	Murine secreted proteins	Murine secreted proteins	495	GDF5_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	220	30	ba	Murine secreted proteins	Murine secreted proteins	454	GDF6_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	577	44	ba	Murine secreted proteins	Murine secreted proteins	461	GDF7_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	414	68	ba	Murine secreted proteins	Murine secreted proteins	376	GDF8_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	623	50	ba	Murine secreted proteins	Murine secreted proteins	441	GDF9_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	120	35	ba	Murine secreted proteins	Murine secreted proteins	211	GDNF_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	89	20	ba	Murine secreted proteins	Murine secreted proteins	142	GMFB_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	54	18	ba	Murine secreted proteins	Murine secreted proteins	142	GMFG_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	368	67	ba	Murine secreted proteins	Murine secreted proteins	96	GROA_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	217	35	ba	Murine secreted proteins	Murine secreted proteins	208	HBEGF_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	2	2	ba	Murine secreted proteins	Murine secreted proteins	237	HDGF_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	11	5	ba	Murine secreted proteins	Murine secreted proteins	202	HDGR3_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	677	63	ba	Murine secreted proteins	Murine secreted proteins	728	HGF_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	237	73	ba	Murine secreted proteins	Murine secreted proteins	153	IGF1_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	186	33	ba	Murine secreted proteins	Murine secreted proteins	180	IGF2_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	366	41	ba	Murine secreted proteins	Murine secreted proteins	199	IL11_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	701	80	ba	Murine secreted proteins	Murine secreted proteins	215	IL12A_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	476	35	ba	Murine secreted proteins	Murine secreted proteins	169	IL2_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	359	67	ba	Murine secreted proteins	Murine secreted proteins	166	IL3_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	475	50	ba	Murine secreted proteins	Murine secreted proteins	235	IL34_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	452	56	ba	Murine secreted proteins	Murine secreted proteins	140	IL4_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	334	41	ba	Murine secreted proteins	Murine secreted proteins	133	IL5_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	411	32	ba	Murine secreted proteins	Murine secreted proteins	211	IL6_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	527	67	ba	Murine secreted proteins	Murine secreted proteins	154	IL7_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	259	38	ba	Murine secreted proteins	Murine secreted proteins	144	IL9_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	863	56	ba	Murine secreted proteins	Murine secreted proteins	366	INHA_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	54	28	ba	Murine secreted proteins	Murine secreted proteins	424	INHBA_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	177	26	ba	Murine secreted proteins	Murine secreted proteins	411	INHBB_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	855	54	ba	Murine secreted proteins	Murine secreted proteins	352	INHBC_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	521	73	ba	Murine secreted proteins	Murine secreted proteins	350	INHBE_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	397	38	ba	Murine secreted proteins	Murine secreted proteins	261	K1KB3_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	281	43	ba	Murine secreted proteins	Murine secreted proteins	256	K1KB4_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	416	43	ba	Murine secreted proteins	Murine secreted proteins	368	LFTY1_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	435	37	ba	Murine secreted proteins	Murine secreted proteins	368	LFTY2_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	418	41	ba	Murine secreted proteins	Murine secreted proteins	203	LIF_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	92	28	ba	Murine secreted proteins	Murine secreted proteins	179	MANF_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	145	24	ba	Murine secreted proteins	Murine secreted proteins	130	MIA_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	499	37	ba	Murine secreted proteins	Murine secreted proteins	298	MIME_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	1072	56	ba	Murine secreted proteins	Murine secreted proteins	554	MIS_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	93	22	ba	Murine secreted proteins	Murine secreted proteins	140	MK_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	297	35	ba	Murine secreted proteins	Murine secreted proteins	241	NGF_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	516	65	ba	Murine secreted proteins	Murine secreted proteins	354	NODAL_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	513	39	ba	Murine secreted proteins	Murine secreted proteins	645	NRG1_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	232	47	ba	Murine secreted proteins	Murine secreted proteins	756	NRG2_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	234	26	ba	Murine secreted proteins	Murine secreted proteins	713	NRG3_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	109	42	ba	Murine secreted proteins	Murine secreted proteins	115	NRG4_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	189	30	ba	Murine secreted proteins	Murine secreted proteins	195	NRTN_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	73	23	ba	Murine secreted proteins	Murine secreted proteins	258	NTF3_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	245	62	ba	Murine secreted proteins	Murine secreted proteins	209	NTF4_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	119	26	ba	Murine secreted proteins	Murine secreted proteins	211	PDGFA_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	276	33	ba	Murine secreted proteins	Murine secreted proteins	241	PDGFB_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	374	35	ba	Murine secreted proteins	Murine secreted proteins	345	PDGFC_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	324	28	ba	Murine secreted proteins	Murine secreted proteins	370	PDGFD_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	230	21	ba	Murine secreted proteins	Murine secreted proteins	158	PLGF_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	56	16	ba	Murine secreted proteins	Murine secreted proteins	105	PROK1_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	233	29	ba	Murine secreted proteins	Murine secreted proteins	156	PSPN_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	63	48	ba	Murine secreted proteins	Murine secreted proteins	168	PTN_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	536	38	ba	Murine secreted proteins	Murine secreted proteins	273	SCF_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	124	39	ba	Murine secreted proteins	Murine secreted proteins	93	SDF1_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	203	65	ba	Murine secreted proteins	Murine secreted proteins	171	TDGF1_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	96	17	ba	Murine secreted proteins	Murine secreted proteins	87	TFF1_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	17	5	ba	Murine secreted proteins	Murine secreted proteins	159	TGFA_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	325	35	ba	Murine secreted proteins	Murine secreted proteins	390	TGFB1_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	280	41	ba	Murine secreted proteins	Murine secreted proteins	414	TGFB2_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	57	14	ba	Murine secreted proteins	Murine secreted proteins	410	TGFB3_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	534	65	ba	Murine secreted proteins	Murine secreted proteins	205	TIMP1_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	448	41	ba	Murine secreted proteins	Murine secreted proteins	963	TSP4_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	341	44	ba	Murine secreted proteins	Murine secreted proteins	392	VEGFA_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	253	17	ba	Murine secreted proteins	Murine secreted proteins	207	VEGFB_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	138	29	ba	Murine secreted proteins	Murine secreted proteins	415	VEGFC_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	297	40	ba	Murine secreted proteins	Murine secreted proteins	358	VEGFD_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	168	31	ba	Murine secreted proteins	Murine secreted proteins	617	VGF_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	499	27	ba	Murine secreted proteins	Murine secreted proteins	308	ADIPL_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	289	40	ba	Murine secreted proteins	Murine secreted proteins	247	ADIPO_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	104	26	ba	Murine secreted proteins	Murine secreted proteins	150	ADM2_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	204	49	ba	Murine secreted proteins	Murine secreted proteins	184	ADML_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	179	47	ba	Murine secreted proteins	Murine secreted proteins	152	ANF_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	194	45	ba	Murine secreted proteins	Murine secreted proteins	121	ANFB_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	85	43	ba	Murine secreted proteins	Murine secreted proteins	126	ANFC_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	415	41	ba	Murine secreted proteins	Murine secreted proteins	198	ANGL8_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	55	19	ba	Murine secreted proteins	Murine secreted proteins	77	APEL_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	169	29	ba	Murine secreted proteins	Murine secreted proteins	333	C1QT9_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	266	31	ba	Murine secreted proteins	Murine secreted proteins	136	CALC_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	258	31	ba	Murine secreted proteins	Murine secreted proteins	128	CALCA_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	236	25	ba	Murine secreted proteins	Murine secreted proteins	130	CALCB_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	262	39	ba	Murine secreted proteins	Murine secreted proteins	115	CCKN_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	196	51	ba	Murine secreted proteins	Murine secreted proteins	235	COLI_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	113	29	ba	Murine secreted proteins	Murine secreted proteins	1224	COPA_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	159	27	ba	Murine secreted proteins	Murine secreted proteins	109	CORT_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	213	33	ba	Murine secreted proteins	Murine secreted proteins	187	CRF_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	69	11	ba	Murine secreted proteins	Murine secreted proteins	54	ELA_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	518	65	ba	Murine secreted proteins	Murine secreted proteins	192	EPO_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	362	22	ba	Murine secreted proteins	Murine secreted proteins	340	ERFE_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	388	38	ba	Murine secreted proteins	Murine secreted proteins	2873	FBN1_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	305	47	ba	Murine secreted proteins	Murine secreted proteins	2907	FBN2_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	6	4	ba	Murine secreted proteins	Murine secreted proteins	209	FNDC5_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	12	4	ba	Murine secreted proteins	Murine secreted proteins	130	FSHB_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	83	21	ba	Murine secreted proteins	Murine secreted proteins	124	GALA_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	79	41	ba	Murine secreted proteins	Murine secreted proteins	117	GALP_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	59	23	ba	Murine secreted proteins	Murine secreted proteins	101	GAST_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	664	79	ba	Murine secreted proteins	Murine secreted proteins	303	GDF15_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	426	24	ba	Murine secreted proteins	Murine secreted proteins	393	GFRAL_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	114	17	ba	Murine secreted proteins	Murine secreted proteins	117	GHRL_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	169	28	ba	Murine secreted proteins	Murine secreted proteins	144	GIP_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	186	39	ba	Murine secreted proteins	Murine secreted proteins	120	GLHA_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	51	10	ba	Murine secreted proteins	Murine secreted proteins	180	GLUC_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	20	12	ba	Murine secreted proteins	Murine secreted proteins	90	GON1_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	82	30	ba	Murine secreted proteins	Murine secreted proteins	128	GPHA2_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	54	16	ba	Murine secreted proteins	Murine secreted proteins	130	GPHB5_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	39	17	ba	Murine secreted proteins	Murine secreted proteins	83	HEPC_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	39	16	ba	Murine secreted proteins	Murine secreted proteins	83	HEPC2_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	290	53	ba	Murine secreted proteins	Murine secreted proteins	93	IAPP_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	186	33	ba	Murine secreted proteins	Murine secreted proteins	180	IGF2_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	863	56	ba	Murine secreted proteins	Murine secreted proteins	366	INHA_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	54	28	ba	Murine secreted proteins	Murine secreted proteins	424	INHBA_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	177	26	ba	Murine secreted proteins	Murine secreted proteins	411	INHBB_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	855	54	ba	Murine secreted proteins	Murine secreted proteins	352	INHBC_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	521	73	ba	Murine secreted proteins	Murine secreted proteins	350	INHBE_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	85	17	ba	Murine secreted proteins	Murine secreted proteins	108	INS1_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	139	27	ba	Murine secreted proteins	Murine secreted proteins	110	INS2_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	272	42	ba	Murine secreted proteins	Murine secreted proteins	122	INSL3_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	86	13	ba	Murine secreted proteins	Murine secreted proteins	135	INSL5_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	132	13	ba	Murine secreted proteins	Murine secreted proteins	191	INSL6_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	309	39	ba	Murine secreted proteins	Murine secreted proteins	141	LSHB_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	276	39	ba	Murine secreted proteins	Murine secreted proteins	165	MCH_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	421	85	ba	Murine secreted proteins	Murine secreted proteins	311	METRL_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	6	3	ba	Murine secreted proteins	Murine secreted proteins	125	NEU1_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	131	24	ba	Murine secreted proteins	Murine secreted proteins	168	NEU2_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	123	18	ba	Murine secreted proteins	Murine secreted proteins	95	OSTC2_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	122	18	ba	Murine secreted proteins	Murine secreted proteins	95	OSTCN_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	174	35	ba	Murine secreted proteins	Murine secreted proteins	130	OSTN_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	198	54	ba	Murine secreted proteins	Murine secreted proteins	175	PACA_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	137	33	ba	Murine secreted proteins	Murine secreted proteins	100	PAHO_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	627	55	ba	Murine secreted proteins	Murine secreted proteins	228	PR2A1_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	586	48	ba	Murine secreted proteins	Murine secreted proteins	228	PR2B1_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	559	41	ba	Murine secreted proteins	Murine secreted proteins	224	PR2C2_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	586	41	ba	Murine secreted proteins	Murine secreted proteins	224	PR2C3_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	774	77	ba	Murine secreted proteins	Murine secreted proteins	222	PR3B1_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	697	78	ba	Murine secreted proteins	Murine secreted proteins	212	PR3C1_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	632	55	ba	Murine secreted proteins	Murine secreted proteins	224	PR3D1_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	609	41	ba	Murine secreted proteins	Murine secreted proteins	227	PR4A1_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	914	69	ba	Murine secreted proteins	Murine secreted proteins	230	PR5A1_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	678	66	ba	Murine secreted proteins	Murine secreted proteins	230	PR6A1_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	486	31	ba	Murine secreted proteins	Murine secreted proteins	266	PR7A1_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	602	46	ba	Murine secreted proteins	Murine secreted proteins	253	PR7A2_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	827	66	ba	Murine secreted proteins	Murine secreted proteins	251	PR7B1_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	898	55	ba	Murine secreted proteins	Murine secreted proteins	251	PR7C1_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	759	53	ba	Murine secreted proteins	Murine secreted proteins	244	PR7D1_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	669	57	ba	Murine secreted proteins	Murine secreted proteins	240	PR8A6_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	987	65	ba	Murine secreted proteins	Murine secreted proteins	241	PR8A8_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	813	87	ba	Murine secreted proteins	Murine secreted proteins	241	PR8A9_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	527	38	ba	Murine secreted proteins	Murine secreted proteins	226	PRL_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	267	75	ba	Murine secreted proteins	Murine secreted proteins	175	PTHR_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	48	18	ba	Murine secreted proteins	Murine secreted proteins	98	PYY_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	275	40	ba	Murine secreted proteins	Murine secreted proteins	185	REL1_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	119	37	ba	Murine secreted proteins	Murine secreted proteins	141	REL3_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	106	52	ba	Murine secreted proteins	Murine secreted proteins	114	RETN_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	92	11	ba	Murine secreted proteins	Murine secreted proteins	111	RETNA_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	31	7	ba	Murine secreted proteins	Murine secreted proteins	105	RETNB_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	38	10	ba	Murine secreted proteins	Murine secreted proteins	117	RETNG_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	200	76	ba	Murine secreted proteins	Murine secreted proteins	133	SECR_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	68	35	ba	Murine secreted proteins	Murine secreted proteins	116	SMS_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	519	45	ba	Murine secreted proteins	Murine secreted proteins	216	SOMA_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	122	20	ba	Murine secreted proteins	Murine secreted proteins	116	SPXN_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	235	56	ba	Murine secreted proteins	Murine secreted proteins	247	STC1_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	146	28	ba	Murine secreted proteins	Murine secreted proteins	296	STC2_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	4570	69	ba	Murine secreted proteins	Murine secreted proteins	2766	THYG_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	504	58	ba	Murine secreted proteins	Murine secreted proteins	231	TOR2X_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	643	40	ba	Murine secreted proteins	Murine secreted proteins	356	TPO_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	184	36	ba	Murine secreted proteins	Murine secreted proteins	256	TRH_MOUSE	NA	NA	NA	170+ AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	99	30	ba	Murine secreted proteins	Murine secreted proteins	138	TSHB_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	194	25	ba	Murine secreted proteins	Murine secreted proteins	147	TTHY_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	137	22	ba	Murine secreted proteins	Murine secreted proteins	122	UCN1_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	340	56	ba	Murine secreted proteins	Murine secreted proteins	113	UCN2_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	226	41	ba	Murine secreted proteins	Murine secreted proteins	164	UCN3_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	293	57	ba	Murine secreted proteins	Murine secreted proteins	123	UTS2_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	162	48	ba	Murine secreted proteins	Murine secreted proteins	113	UTS2B_MOUSE	NA	NA	NA	50-170 AAs
4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	231	53	ba	Murine secreted proteins	Murine secreted proteins	170	VIP_MOUSE	NA	NA	NA	50-170 AAs
